

# Prueba científica de la vacuna Contra el Covid letal

---

- Post published: 5 enero 2022

## Vacunas contra la COVID-19: prueba científica de letalidad

Publicación de la entrada: 5 enero 2022 a las <https://www.saveusnow.org.uk/covid-vaccine-scientific-proof-lethal>

### **Más de mil estudios científicos demuestran que las vacunas contra el COVID-19 son peligrosas, y todos los que impulsan esta agenda están cometiendo el delito imputable de mala conducta grave en los cargos públicos.**

Poco más de 12 meses desde el despliegue de las vacunas experimentales de uso de emergencia COVID 19, los estudios científicos en miles y los informes de denuncias penales de asalto y asesinato por el uso ilegal e ilegal de venenos bioquímicos hechos a las fuerzas policiales de todo el país, verifican un asalto a una población desprevenida del Reino Unido. La ciencia irrefutable muestra que la vacuna COVID 19 no es segura ni efectiva para limitar la transmisión o la infección por los patógenos del coronavirus SARS-CoV-2.

La falsa propaganda "segura y efectiva", difundida por funcionarios públicos que ahora continúan impulsando esta vacuna, es un claro incumplimiento del deber. El titular de un cargo público está sujeto y es consciente de un deber de prevenir la muerte o las lesiones graves que surjan únicamente en virtud de las funciones del cargo público.

Muchos han incumplido ese deber y, al hacerlo, están causando imprudentemente un riesgo de muerte o lesiones graves, al continuar independientemente de los peligros ahora confirmados asociados con las inyecciones de COVID 19. Algunos de estos riesgos son **coagulación de la sangre, miocarditis, pericarditis, trombosis, trombocitopenia, anafilaxia, parálisis de Bell, Guillain-Barré, cáncer incluyendo muertes, etc.**

Todo esto se confirma en los siguientes datos recopilados por la ciencia y el gobierno de la agencia de Salud y Seguridad del Reino Unido sobre COVID 19 con respecto al daño de la vacuna.

El término "vacuna" se cambió recientemente para incorporar este experimento médico ilegal e ilegal para facilitar el uso de la tecnología de ARNm que demostrablemente no es una vacuna, y que contiene nanometá materiales biológicamente tóxicos asociados con la capacidad de recopilación de datos urbanos 5G.

Las nanopartículas metálicas son conocidas en la ciencia por ser genotóxicas, un veneno que también puede causar esterilización. Los peligros que representan para las víctimas a corto plazo esta agresión médica ya se conocen. Sin embargo, la letalidad a largo plazo de esta arma aún no se ha realizado debido a los efectos debilitantes que tiene sobre el sistema inmunológico, causando el Síndrome de Inmunodeficiencia Adquirida (SIDA).

Ahora podemos confirmar los documentos de inteligencia de defensa de la despoblación de 2017, que muestran el asesinato planificado de más de 55 millones en todo el Reino Unido para 2025 utilizando esta arma bioquímica.

La Agencia Reguladora de Medicamentos y Salud (productos) (MHRA) había advertido previamente del gran número esperado de reacciones adversas antes del despliegue, lo que confirma la naturaleza premeditada del delito y los delitos de conducta pública entonces y ahora.

1. Trombosis venosa cerebral después de la vacunación contra la COVID-19 en el Reino Unido: un estudio de cohorte multicéntrico: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)01608-1/](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/)
2. Trombocitopenia trombótica inmunológica inducida por vacunación con coagulación intravascular diseminada y muerte después de la vacunación con ChAdOx1 nCoV-19: <https://www.sciencedirect.com/science/article/pii/S1052305721003414>
3. Hemorragia cerebral fatal después de la vacuna COVID-19: <https://pubmed.ncbi.nlm.nih.gov/33928772/>
4. Miocarditis después de la vacunación con ARNm contra el SARS-CoV-2, una serie de casos: <https://www.sciencedirect.com/science/article/pii/S2666602221000409>
5. Tres casos de tromboembolismo venoso agudo en mujeres después de la vacunación contra COVID-19: <https://www.sciencedirect.com/science/article/pii/S2213333X21003929>
6. Trombosis aguda del árbol coronario después de la vacunación contra COVID-19: <https://www.sciencedirect.com/science/article/abs/pii/S1936879821003988>
7. Informes de casos estadounidenses de trombosis del seno venoso cerebral con trombocitopenia después de la vacunación con Ad26.COV2.S (contra covid-19), del 2 de marzo al 21 de abril de 2020: <https://pubmed.ncbi.nlm.nih.gov/33929487/>
8. Trombosis de la vena porta asociada con la vacuna ChAdOx1 nCov-19: [https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(21\)00197-7/](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/)
9. Manejo de la trombosis venosa cerebral y esplácnica asociada con trombocitopenia en sujetos previamente vacunados con Vaxzevria (AstraZeneca): declaración de posición de la Sociedad Italiana para el Estudio de la Hemostasia y la Trombosis (SISSET): <https://pubmed.ncbi.nlm.nih.gov/33871350/>
10. Trombocitopenia inmunitaria trombótica inducida por vacunación y trombosis del seno venoso cerebral después de la vacunación con COVID-19; una revisión sistemática: <https://www.sciencedirect.com/science/article/pii/S0022510X21003014>
11. Trombosis con síndrome de trombocitopenia asociada a las vacunas contra la COVID-19: <https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381>
12. Trombosis y trombocitopenia inducidas por la vacuna contra la Covid-19: un comentario sobre un dilema clínico importante y práctico: <https://www.sciencedirect.com/science/article/abs/pii/S0033062021000505>
13. Trombosis con síndrome de trombocitopenia asociada a vacunas de vectores virales COVID-19: <https://www.sciencedirect.com/science/article/abs/pii/S0953620521001904>
14. Trombocitopenia trombótica inmunológica inducida por la vacuna COVID-19: una causa emergente de trombosis venosa esplácnica: <https://www.sciencedirect.com/science/article/pii/S1665268121000557>
15. El papel de las plaquetas en la coagulopatía asociada a COVID-19 y la trombocitopenia inmune trombótica inducida por la vacuna (covid): <https://www.sciencedirect.com/science/article/pii/S1050173821000967>
16. Raíces de la autoinmunidad de los eventos trombóticos después de la vacunación contra el COVID-19: <https://www.sciencedirect.com/science/article/abs/pii/S1568997221002160>
17. Trombosis del seno venoso cerebral después de la vacunación: la experiencia del Reino Unido: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)01788-8/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext)
18. Trombocitopenia inmunitaria trombótica inducida por la vacuna contra el SARS-CoV-2: <https://www.nejm.org/doi/full/10.1056/nejme2106315>
19. Miocarditis después de la inmunización con vacunas de ARNm COVID-19 en miembros del ejército de los Estados Unidos. Este artículo informa que en "23 pacientes masculinos, incluidos 22 miembros militares previamente sanos, se identificó miocarditis dentro de los 4 días posteriores a la recepción de la vacuna": <https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601>
20. Trombosis y trombocitopenia después de la vacunación con ChAdOx1 nCoV-19: [https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc\\_curatedRelated\\_article](https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelated_article)
21. Asociación de la miocarditis con la vacuna BNT162b2 arn mensajero COVID-19 en una serie de casos de niños: <https://pubmed.ncbi.nlm.nih.gov/34374740/>
22. Trombocitopenia trombótica después de la vacunación con ChAdOx1 nCov-19: [https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc\\_curatedRelated\\_article](https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelated_article)
23. Hallazgos post mortem en la trombocitopenia trombótica inducida por la vacuna (covid-19): <https://haematologica.org/article/view/haematol.2021.279075>
24. Trombocitopenia, incluida la trombocitopenia inmune después de recibir las vacunas de ARNm contra la COVID-19 notificadas al Sistema de Notificación de Eventos Adversos a las Vacunas (VAERS): <https://www.sciencedirect.com/science/article/pii/S0264410X21005247>

25. Miocarditis sintomática aguda en siete adolescentes tras la vacunación Pfizer-BioNTech contra la COVID-19: <https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478>
26. Afasia siete días después de la segunda dosis de una vacuna contra el SARS-CoV-2 basada en ARNm. La resonancia magnética cerebral reveló una hemorragia intracerebral (ICBH) en el lóbulo temporal izquierdo en un hombre de 52 años. <https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005>
27. Comparación de los episodios trombóticos inducidos por la vacuna entre las vacunas ChAdOx1 nCoV-19 y Ad26.COV.2.S: <https://www.sciencedirect.com/science/article/abs/pii/S0896841121000895>
28. Hipótesis detrás de los casos muy raros de trombosis con síndrome de trombocitopenia después de la vacunación contra el SARS-CoV-2: <https://www.sciencedirect.com/science/article/abs/pii/S0049384821003315>
29. Coágulos sanguíneos y episodios hemorrágicos tras la vacunación con BNT162b2 y ChAdOx1 nCoV-19: análisis de datos europeos: <https://www.sciencedirect.com/science/article/pii/S0896841121000937>
30. Trombosis venosa cerebral después de la vacuna BNT162b2 mRNA SARS-CoV-2: <https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098>
31. Insuficiencia suprarrenal primaria asociada con trombocitopenia inmune trombótica inducida por la vacuna Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT): <https://www.sciencedirect.com/science/article/pii/S0953620521002363>
32. Miocarditis y pericarditis después de la vacunación con ARNm DE COVID-19: consideraciones prácticas para los proveedores de atención: <https://www.sciencedirect.com/science/article/pii/S0828282X21006243>
33. "Trombosis de la vena porta que ocurre después de la primera dosis de la vacuna de ARNm contra el SARS-CoV-2 en un paciente con síndrome antifosfolípido": <https://www.sciencedirect.com/science/article/pii/S2666572721000389>
34. Resultados tempranos del tratamiento con bivalirudina para la trombocitopenia trombótica y la trombosis venosa cerebral después de la vacunación con Ad26.COV.2.S: <https://www.sciencedirect.com/science/article/pii/S0196064421003425>
35. Miocarditis, pericarditis y miocardiopatía después de la vacunación contra el COVID-19: <https://www.sciencedirect.com/science/article/pii/S1443950621011562>
36. Mecanismos de inmunotrombosis en la trombocitopenia trombótica inducida por vacunación (VITT) en comparación con la infección natural por SARS-CoV-2: <https://www.sciencedirect.com/science/article/abs/pii/S0896841121000706>
37. Trombocitopenia inmunitaria protrombótica después de la vacunación contra la COVID-19: <https://www.sciencedirect.com/science/article/pii/S0006497121009411>
38. Trombocitopenia trombótica inducida por vacunas: el capítulo oscuro de una historia de éxito: <https://www.sciencedirect.com/science/article/pii/S2589936821000256>
39. Trombosis venosa cerebral negativa para anticuerpos anti-PF4 sin trombocitopenia después de la inmunización con la vacuna COVID-19 en un hombre indio de edad avanzada no comórbido tratado con anticoagulación convencional a base de heparina-warfarina: <https://www.sciencedirect.com/science/article/pii/S1871402121002046>
40. Trombosis después de la vacunación contra la COVID-19: posible vínculo con las vías de la ECA: <https://www.sciencedirect.com/science/article/pii/S0049384821004369>
41. Trombosis venosa cerebral en la población estadounidense después de la vacunación contra el SARS-CoV-2 con adenovirus y después de COVID-19: <https://www.sciencedirect.com/science/article/pii/S0735109721051949>
42. Un caso raro de un hombre asiático de mediana edad con trombosis venosa cerebral después de la vacunación contra el COVID-19 de AstraZeneca: <https://www.sciencedirect.com/science/article/pii/S0735675721005714>
43. Trombosis del seno venoso cerebral y trombocitopenia tras la vacunación contra la COVID-19: informe de dos casos en el Reino Unido: <https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X>
44. Púrpura trombocitopénica inmune después de la vacunación con la vacuna contra la COVID-19 (ChAdOx1 nCov-19): <https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963>
45. Anticuerpos antifosfolípidos y riesgo de trombofilia tras la vacunación contra el COVID-19: ¿la gota que colma el vaso?: <https://docs.google.com/document/d/1XzajasO8VMMn3CdxSBKks1o7kiOLXFQ>
46. Trombocitopenia trombótica inducida por vacunas, un caso raro pero grave de fuego amigo en la batalla contra la pandemia de COVID-19: ¿Qué patogénesis?: <https://www.sciencedirect.com/science/article/pii/S0953620521002314>

47. Recomendaciones diagnóstico-terapéuticas del grupo de trabajo de expertos ad-hoc FACME sobre el manejo de la trombosis venosa cerebral relacionada con la vacunación contra la COVID-19: <https://www.sciencedirect.com/science/article/pii/S0213485321000839>
48. Trombocitopenia y trombosis venosa intracraneal tras la exposición a la "vacuna AstraZeneca COVID-19": <https://pubmed.ncbi.nlm.nih.gov/33918932/>
49. Trombocitopenia tras la vacunación contra el SARS-CoV-2 de Pfizer y Moderna: <https://pubmed.ncbi.nlm.nih.gov/33606296/>
50. Trombocitopenia inmune grave y refractaria que ocurre después de la vacunación contra el SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/33854395/>
51. Erupción purpúrica y trombocitopenia después de la vacuna CONTRA el COVID-19 mRNA-1273 (moderna): <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/>
52. Vacunación contra la COVID-19: información sobre la aparición de trombosis arterial y venosa utilizando datos de VigiBase: <https://pubmed.ncbi.nlm.nih.gov/33863748/>
53. Trombosis venosa cerebral asociada a la vacuna contra la covid-19 en Alemania: <https://onlinelibrary.wiley.com/doi/10.1002/ana.26172>
54. Trombosis venosa cerebral tras la vacunación con ARNm BNT162b2 de BNT162b2 contra el SARS-CoV-2: un evento de cisne negro: <https://pubmed.ncbi.nlm.nih.gov/34133027/>
55. La importancia de reconocer la trombosis venosa cerebral después de la vacunación anti-COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34001390/>
56. Trombosis con trombocitopenia después de la vacuna de ARN mensajero - 1273: <https://pubmed.ncbi.nlm.nih.gov/34181446/>
57. Coágulos sanguíneos y sangrado después de la vacunación BNT162b2 y ChAdOx1 nCoV-19: un análisis de datos europeos: <https://pubmed.ncbi.nlm.nih.gov/34174723/>
58. Primera dosis de las vacunas ChAdOx1 y BNT162b2 contra la COVID-19 y eventos trombocitopénicos, tromboembólicos y hemorrágicos en Escocia: <https://www.nature.com/articles/s41591-021-01408-4>
59. Exacerbación de la trombocitopenia inmune después de la vacunación contra la COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34075578/>
60. Primer informe de un episodio de iTTP de novo asociado con una vacuna anti-COVID-19 basada en ARNm COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34105244/>
61. Inmunoensayos PF4 en trombocitopenia trombótica inducida por vacunación: <https://www.nejm.org/doi/full/10.1056/NEJMc2106383>
62. Epítomos de anticuerpos en la trombocitopenia trombótica inmune inducida por vacunas: <https://www.nature.com/articles/s41586-021-03744-4>
63. Miocarditis con vacunas de ARNm contra la COVID-19: <https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135>
64. Miocarditis y pericarditis después de la vacunación contra la COVID-19: <https://jamanetwork.com/journals/jama/fullarticle/2782900>
65. Miocarditis asociada temporalmente a la vacunación contra la COVID-19: <https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891>
66. Vacunación contra la COVID-19 asociada con la miocarditis en adolescentes: <https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.2021-053427.full.pdf>
67. Miocarditis aguda tras la administración de la vacuna BNT162b2 contra la COVID-19: <https://pubmed.ncbi.nlm.nih.gov/33994339/>
68. Asociación temporal entre la vacuna contra la COVID-19 Ad26.COV2.S y la miocarditis aguda: informe de caso y revisión de la literatura: <https://www.sciencedirect.com/science/article/pii/S1553838921005789>
69. Miocarditis inducida por la vacuna COVID-19: un informe de caso con revisión de la literatura: <https://www.sciencedirect.com/science/article/pii/S1871402121002253>
70. Posible asociación entre la vacuna contra la COVID-19 y la miocarditis: hallazgos clínicos y de CMR: <https://www.sciencedirect.com/science/article/pii/S1936878X2100485X>
71. Recurrencia de la miocarditis aguda asociada temporalmente con la recepción de la vacuna contra la enfermedad por coronavirus mRNA 2019 (COVID-19) en un adolescente masculino: <https://www.sciencedirect.com/science/article/pii/S002234762100617X>
72. Miocarditis fulminante e hiperinflamación sistémica asociada temporalmente a la vacunación con ARNm BNT162b2 COVID-19 en dos pacientes: <https://www.sciencedirect.com/science/article/pii/S0167527321012286>
73. Miocarditis aguda después de la administración de la vacuna BNT162b2: <https://www.sciencedirect.com/science/article/pii/S2214250921001530>

74. Myocarditis linfocítica después de la vacunación con COVID-19 Ad26.COVS vector viral: <https://www.sciencedirect.com/science/article/pii/S2352906721001573>
75. Myocarditis después de la vacunación con BNT162b2 en un hombre sano: <https://www.sciencedirect.com/science/article/pii/S0735675721005362>
76. Myocarditis aguda después de la vacunación de Comirnaty (Pfizer) en un hombre sano con infección previa por SARS-CoV-2: <https://www.sciencedirect.com/science/article/pii/S1930043321005549>
77. Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents: <https://www.sciencedirect.com/science/article/pii/S002234762100665X>
78. Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine: <https://www.sciencedirect.com/science/article/pii/S1885585721002218>
79. Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA: <https://www.sciencedirect.com/science/article/pii/S2589790X21001931>
80. Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection: <https://www.sciencedirect.com/science/article/pii/S2352906721000622>
81. Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age: <https://www.sciencedirect.com/science/article/pii/S0022347621007368>
82. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man: <https://www.sciencedirect.com/science/article/pii/S0870255121003243>
83. Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents: <https://www.sciencedirect.com/science/article/pii/S0022347621007496>
84. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: <https://www.sciencedirect.com/science/article/pii/S1936878X21004861>
85. Takotsubo cardiomyopathy after vaccination with mRNA COVID-19: <https://www.sciencedirect.com/science/article/pii/S1443950621011331>
86. COVID-19 mRNA vaccination and myocarditis: <https://pubmed.ncbi.nlm.nih.gov/34268277/>
87. COVID-19 vaccine and myocarditis: <https://pubmed.ncbi.nlm.nih.gov/34399967/>
88. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study <https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-1360706>.
89. COVID-19 vaccines and myocarditis: <https://pubmed.ncbi.nlm.nih.gov/34246566/>
90. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines <https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-complications-of-the-mrna-based-covid-19-vaccines> <https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-complications-of-the-mrna-based-covid-19-vaccines>
91. Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34340927/>
92. Myocarditis with covid-19 mRNA vaccines: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135>
93. Association of myocarditis with COVID-19 mRNA vaccine in children: <https://media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-covid-19-vaccine-in-children/>
94. Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children: <https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052>
95. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S. military: <https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C>
96. Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines: <https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600>
97. Myocarditis following immunization with Covid-19 mRNA: <https://www.nejm.org/doi/full/10.1056/NEJMc2109975>
98. Patients with acute myocarditis after vaccination with COVID-19 mRNA: <https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602>
99. Myocarditis associated with vaccination with COVID-19 mRNA: <https://pubs.rsna.org/doi/10.1148/radiol.2021211430>
100. Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination: <https://pediatrics.aappublications.org/content/148/3/e2021052478>
101. Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: <https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-021-00795-4>

102. Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA: <https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-with-myocarditis-and-pericarditis>
103. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: <https://pubmed.ncbi.nlm.nih.gov/34402228/>
104. Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine: <https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567>
105. Myocarditis / pericarditis associated with COVID-19 vaccine: [https://science.gc.ca/eic/site/063.nsf/eng/h\\_98291.html](https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html)
106. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: [https://journals.lww.com/pidj/Abstract/9000/Transient\\_Cardiac\\_Injury\\_in\\_Adolescents\\_Receiving.95800.aspx](https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolescents_Receiving.95800.aspx)
107. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: <https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543>
108. The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism: <https://pubmed.ncbi.nlm.nih.gov/34312010/>
109. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database: <https://pubmed.ncbi.nlm.nih.gov/34219532/>
110. Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination: <https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033>
111. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings: <https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236>
112. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038>
113. Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?: <https://pubmed.ncbi.nlm.nih.gov/34333695/>
114. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/>
115. Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?: <https://pubmed.ncbi.nlm.nih.gov/34118375/>
116. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34180390/>
117. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: <https://pubmed.ncbi.nlm.nih.gov/34133825/>
118. Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report: <https://pubmed.ncbi.nlm.nih.gov/34487236/>
119. Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059>
120. Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34447639/>
121. Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report: <https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183>
122. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: <https://pubmed.ncbi.nlm.nih.gov/34236331/>
123. Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34435250/>
124. COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: <https://pubmed.ncbi.nlm.nih.gov/34186348/>.
125. GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: <https://www.sciencedirect.com/science/article/pii/S2666354621000065>
126. Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: <https://www.sciencedirect.com/science/article/pii/S0303846721004169>

127. Sensory Guillain-Barré syndrome after ChAdOx1 nCoV-19 vaccine: report of two cases and review of the literature: <https://www.sciencedirect.com/science/article/pii/S0165572821002186>
128. Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: <https://www.sciencedirect.com/science/article/pii/S2214250921000998>.
129. Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: <https://www.sciencedirect.com/science/article/pii/S0736467921006442>
130. Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: <https://www.sciencedirect.com/science/article/pii/S0035378721005853>.
131. SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: <https://www.sciencedirect.com/science/article/pii/S2049080121005343>
132. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: <https://www.sciencedirect.com/science/article/pii/S2049080121007536>
133. Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: <https://www.sciencedirect.com/science/article/pii/S1201971221007049>
134. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: <https://www.sciencedirect.com/science/article/pii/S0899707121003557>.
135. New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination: <https://www.sciencedirect.com/science/article/pii/S0165572821001569>
136. Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: <https://www.sciencedirect.com/science/article/pii/S0165572821002137>
137. Bell's palsy and SARS-CoV-2 vaccines: an unfolding story: <https://www.sciencedirect.com/science/article/pii/S1473309921002735>
138. Bell's palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell's palsy: <https://www.sciencedirect.com/science/article/pii/S266635462100020X>
139. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine: <https://www.sciencedirect.com/science/article/pii/S2451993621001456>.
140. Bell's palsy after COVID-19 vaccination: case report: <https://www.sciencedirect.com/science/article/pii/S217358082100122X>.
141. An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient's allergy history: <https://www.sciencedirect.com/science/article/pii/S2213219821007972>
142. COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET: <https://www.sciencedirect.com/science/article/pii/S1930043321002612>
143. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: <https://www.sciencedirect.com/science/article/pii/S0272638621007423>
144. Late cutaneous reactions after administration of COVID-19 mRNA vaccines: <https://www.sciencedirect.com/science/article/pii/S2213219821007996>
145. COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature: <https://www.sciencedirect.com/science/article/pii/S1871402121001880>
146. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: <https://www.sciencedirect.com/science/article/pii/S0190962221024427>
147. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: <https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381>.
148. COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization: <https://www.sciencedirect.com/science/article/pii/S1939455121000119>.
149. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation: <https://www.sciencedirect.com/science/article/pii/S1871402121002046>.
150. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: <https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X>
151. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data: <https://www.sciencedirect.com/science/article/pii/S0896841121000937>.
152. immune thrombocytopenia associated with Pfizer-BioNTech's COVID-19 BNT162b2 mRNA vaccine: <https://www.sciencedirect.com/science/article/pii/S2214250921002018>.
153. Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report: <https://www.sciencedirect.com/science/article/pii/S1876034121001878>.

154. COVID-19 RNA-based vaccines and the risk of prion disease: <https://scivisionpub.com/pdfs/covid19rna-based-vaccines-and-the-risk-of-prion-disease-1503.pdf>
155. This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines: <https://www.nejm.org/doi/full/10.1056/NEJMoa2104983>.
156. Process-related impurities in the ChAdOx1 nCov-19 vaccine: <https://www.researchsquare.com/article/rs-477964/v1>
157. COVID-19 mRNA vaccine causing CNS inflammation: a case series: <https://link.springer.com/article/10.1007/s00415-021-10780-7>
158. Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33475702/>
159. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol: <https://pubmed.ncbi.nlm.nih.gov/33320974/>
160. Pfizer Vaccine Raises Allergy Concerns: <https://pubmed.ncbi.nlm.nih.gov/33384356/>
161. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020: <https://pubmed.ncbi.nlm.nih.gov/33444297/>
162. Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021: <https://pubmed.ncbi.nlm.nih.gov/33507892/>
163. Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: <https://pubmed.ncbi.nlm.nih.gov/34414880/>
164. Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: <https://pubmed.ncbi.nlm.nih.gov/33576785/>
165. Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: <https://pubmed.ncbi.nlm.nih.gov/34269740/>
166. Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34215453/>
167. Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: <https://pubmed.ncbi.nlm.nih.gov/33932618/>
168. Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): <https://pubmed.ncbi.nlm.nih.gov/33643776/>
169. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: <https://pubmed.ncbi.nlm.nih.gov/33571463/>
170. Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: <https://pubmed.ncbi.nlm.nih.gov/33527524/>
171. Cutaneous adverse effects of available COVID-19 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34518015/>
172. Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: <https://pubmed.ncbi.nlm.nih.gov/34347278/>
173. COVID-19 vaccines increase the risk of anaphylaxis: <https://pubmed.ncbi.nlm.nih.gov/33685103/>
174. Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34050949/>
175. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation: <https://pubmed.ncbi.nlm.nih.gov/33657648/>
176. Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33825239/>
177. Acute allergic reactions to COVID-19 mRNA vaccines: <https://pubmed.ncbi.nlm.nih.gov/33683290/>
178. Polyethylene glycol allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2: <https://pubmed.ncbi.nlm.nih.gov/33919151/>
179. Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: <https://pubmed.ncbi.nlm.nih.gov/34128049/>



180. Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: <https://pubmed.ncbi.nlm.nih.gov/34474708/>
181. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI): <https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447>
182. .IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: <https://pubmed.ncbi.nlm.nih.gov/34318537/>
183. Allergic reactions after COVID-19 vaccination: putting the risk in perspective: <https://pubmed.ncbi.nlm.nih.gov/34463751/>
184. Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: <https://pubmed.ncbi.nlm.nih.gov/33846043/> 188.
185. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: <https://pubmed.ncbi.nlm.nih.gov/33752263/>
186. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: <https://pubmed.ncbi.nlm.nih.gov/34073536/>
187. Fatal brain hemorrhage after COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33928772/>
188. A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: <https://pubmed.ncbi.nlm.nih.gov/34423106/>
189. Skin reactions reported after Moderna and Pfizer's COVID-19 vaccination: a study based on a registry of 414 cases: <https://pubmed.ncbi.nlm.nih.gov/33838206/>
190. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: <https://pubmed.ncbi.nlm.nih.gov/34517079/>
191. Skin reactions after vaccination against SARS-CoV-2: a nationwide Spanish cross-sectional study of 405 cases: <https://pubmed.ncbi.nlm.nih.gov/34254291/>
192. Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: <https://pubmed.ncbi.nlm.nih.gov/34487581/>
193. Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: <https://pubmed.ncbi.nlm.nih.gov/33987882/>
194. Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34138513/>
195. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: <https://pubmed.ncbi.nlm.nih.gov/34402235/>
196. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: <https://pubmed.ncbi.nlm.nih.gov/34446426/>
197. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: <https://pubmed.ncbi.nlm.nih.gov/34365148/>.
198. Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: <https://pubmed.ncbi.nlm.nih.gov/34452064/>.
199. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33917902/>
200. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): <https://pubmed.ncbi.nlm.nih.gov/34256983/>
201. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34247246/>.
202. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34132839/>
203. 59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34117206/>
204. Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: <https://pubmed.ncbi.nlm.nih.gov/34033927/>
205. Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34277198/>

206. Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34364831/>
207. Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: <https://pubmed.ncbi.nlm.nih.gov/34447639/>
208. Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: <https://pubmed.ncbi.nlm.nih.gov/34514306/>
209. Brotes de enfermedades inmunomediadas o enfermedades de inicio reciente en 27 sujetos después de la vacunación de ARNm/ADN contra el SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/33946748/>
210. Información de un modelo murino de miopericarditis inducida por la vacuna de ARNm COVID-19: ¿podría la inyección intravenosa accidental de una vacuna inducir miopericarditis: <https://pubmed.ncbi.nlm.nih.gov/34453510/>
211. Trombocitopenia inmune en una vacuna post Covid-19 de 22 años: <https://pubmed.ncbi.nlm.nih.gov/33476455/>
212. vasculitis asociada a anticuerpos anticitoplasmáticos de neutrófilos inducida por propiltiouracilo después de la vacunación contra la COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34451967/>
213. Trombocitopenia inmune secundaria (PTI) asociada a la vacuna ChAdOx1 Covid-19: informe de caso: <https://pubmed.ncbi.nlm.nih.gov/34377889/>
214. Trombosis con síndrome de trombocitopenia (TTS) tras la vacunación contra la COVID-19 de AstraZeneca ChAdOx1 nCoV-19 (AZD1222): análisis de riesgo-beneficio para personas <60 años en Australia: <https://pubmed.ncbi.nlm.nih.gov/34272095/>
215. Asociación de vacunación contra la COVID-19 y parálisis del nervio facial: un estudio de casos y controles: <https://pubmed.ncbi.nlm.nih.gov/34165512/>
216. La asociación entre la vacunación contra la COVID-19 y la parálisis de Bell: <https://pubmed.ncbi.nlm.nih.gov/34411533/>
217. Parálisis de Bell después de la vacunación contra el COVID-19: <https://pubmed.ncbi.nlm.nih.gov/33611630/>
218. Mielitis transversa aguda (ATM): revisión clínica de 43 pacientes con ATM asociada a COVID-19 y 3 eventos adversos graves de ATM posterior a la vacunación con la vacuna ChAdOx1 nCoV-19 (AZD1222): <https://pubmed.ncbi.nlm.nih.gov/33981305/>
219. Parálisis de Bell después de 24 horas de la vacuna mRNA-1273 SARS-CoV-2 mRNA-1273: <https://pubmed.ncbi.nlm.nih.gov/34336436/>
220. Parálisis secuencial del nervio facial contralateral después de la primera y segunda dosis de la vacuna COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34281950/>
221. Mielitis transversa inducida por la vacunación contra el SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34458035/>
222. Parálisis del nervio facial periférico después de la vacunación con BNT162b2 (COVID-19): <https://pubmed.ncbi.nlm.nih.gov/33734623/>
223. Parálisis nerviosa aguda por abducens después de la vacunación contra la COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34044114/>
224. Parálisis del nervio facial después de la administración de vacunas de ARNm COVID-19: análisis de la base de datos de autoinforme: <https://pubmed.ncbi.nlm.nih.gov/34492394/>
225. Parálisis oculomotora transitoria después de la administración de la vacuna mensajera DE ARNm-1273 para la diplopía del SARS-CoV-2 después de la vacuna contra la COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34369471/>
226. Parálisis de Bell después de la vacunación contra el COVID-19 de Ad26.COV2.S: <https://pubmed.ncbi.nlm.nih.gov/34014316/>
227. Parálisis de Bell después de la vacunación contra el COVID-19: informe de caso: <https://pubmed.ncbi.nlm.nih.gov/34330676/>
228. Un caso de polirradiculoneuropatía desmielinizante aguda con parálisis facial bilateral después de la vacunación ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34272622/>
229. Síndrome de Guillian Barré tras la vacunación con ARNm-1273 contra la COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34477091/>
230. Parálisis facial aguda como posible complicación de la vacunación contra el SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/33975372/>
231. Parálisis de Bell después de la vacunación contra el COVID-19 con alta respuesta de anticuerpos en LCR: <https://pubmed.ncbi.nlm.nih.gov/34322761/>

232. Síndrome de Parsonage-Turner asociado con la vacunación contra el SARS-CoV-2 o el SARS-CoV-2. Comentario sobre: "Amiotrofia neurálgica e infección por COVID-19: 2 casos de parálisis nerviosa espinal accesoria" por Coll et al. *Articular Spine* 2021; 88: 10519: <https://pubmed.ncbi.nlm.nih.gov/34139321/>.
233. Parálisis de Bell después de una dosis única de ARNm de la vacuna. SARS-CoV-2: caso clínico: <https://pubmed.ncbi.nlm.nih.gov/34032902/>.
234. Hepatitis autoinmune en desarrollo después de la vacuna contra la enfermedad por coronavirus 2019 (COVID-19): ¿causalidad o víctima?: <https://pubmed.ncbi.nlm.nih.gov/33862041/>
235. Hepatitis autoinmune desencadenada por la vacunación contra el SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34332438/>
236. Hepatitis autoinmune aguda con anticuerpos antimitocondriales atípicos tras la vacunación con ARNm de COVID-19: una nueva entidad clínica: <https://pubmed.ncbi.nlm.nih.gov/34293683/>.
237. Autoimmune hepatitis after COVID vaccine: <https://pubmed.ncbi.nlm.nih.gov/34225251/>
238. A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34449715/>
239. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: <https://pubmed.ncbi.nlm.nih.gov/34139631/>.
240. Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/33864750/>
241. Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/33914590/>
242. Venous sinus thrombosis after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34420802/>
243. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: <https://pubmed.ncbi.nlm.nih.gov/34293217/>
244. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: <https://pubmed.ncbi.nlm.nih.gov/34446426/>
245. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: <https://pubmed.ncbi.nlm.nih.gov/34174723/>
246. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: <https://pubmed.ncbi.nlm.nih.gov/33952445/>
247. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: <https://pubmed.ncbi.nlm.nih.gov/34108714/>
248. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: <https://pubmed.ncbi.nlm.nih.gov/34288044/>
249. Malignant cerebral infarction after vaccination with ChAdOx1 nCoV-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34341358/>
250. celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: <https://pubmed.ncbi.nlm.nih.gov/34261633/>.
251. Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34256983/>
252. Thrombocytopenia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34332437/>.
253. Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33845870/>.
254. Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: <https://pubmed.ncbi.nlm.nih.gov/34236343/>
255. Acute myocardial infarction within 24 hours after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34364657/>.
256. Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34287612/>
257. central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: <https://pubmed.ncbi.nlm.nih.gov/34478433/>
258. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: <https://pubmed.ncbi.nlm.nih.gov/34402235/>

259. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: <https://pubmed.ncbi.nlm.nih.gov/34186376/>
260. Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34101024/>
261. A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34137813/>
262. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34191218/>
263. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCoV-19 vaccine: impact on recanalization strategy: <https://pubmed.ncbi.nlm.nih.gov/34175640/>
264. New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34153802/>
265. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: <https://pubmed.ncbi.nlm.nih.gov/34092488/>
266. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34261635/>
267. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34132839/>
268. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34144250/>
269. Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/33687691/>
270. Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34011137/>
271. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: <https://pubmed.ncbi.nlm.nih.gov/34393988/>
272. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34129181/>
273. Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from the French network of regional pharmacovigilance centers: <https://pubmed.ncbi.nlm.nih.gov/34083026/>
274. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34247246/>
275. Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage: <https://pubmed.ncbi.nlm.nih.gov/34235757/>
276. Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34473841/>
277. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34189756/>
278. Cerebral venous thrombosis following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34045111/>
279. Lipschütz ulcers after AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34366434/>
280. Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34330677/>
281. Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: <https://pubmed.ncbi.nlm.nih.gov/34181446/>
282. Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34477089/>
283. Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: <https://pubmed.ncbi.nlm.nih.gov/34071883/>
284. Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): <https://pubmed.ncbi.nlm.nih.gov/34033367/>
285. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: <https://pubmed.ncbi.nlm.nih.gov/34375510/>

286. Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34107198/>
287. Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34355379/>.
288. A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: <https://pubmed.ncbi.nlm.nih.gov/34452028/>
289. Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: <https://pubmed.ncbi.nlm.nih.gov/34202817/>
290. Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34237213/>.
291. Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34105247/>.
292. Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34405870/>.
293. Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34416410/>.
294. Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: <https://pubmed.ncbi.nlm.nih.gov/34462013/>.
295. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34224024/>.
296. Post-vaccinal encephalitis after ChAdOx1 nCov-19: <https://pubmed.ncbi.nlm.nih.gov/34324214/>
297. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: <https://pubmed.ncbi.nlm.nih.gov/34507266/>
298. Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: <https://pubmed.ncbi.nlm.nih.gov/34459725/>
299. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34463066/>
300. Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: <https://pubmed.ncbi.nlm.nih.gov/34043800/>.
301. Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COVS.2.S vaccine: <https://pubmed.ncbi.nlm.nih.gov/34447646/>
302. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: <https://pubmed.ncbi.nlm.nih.gov/34479760/>.
303. fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: <https://pubmed.ncbi.nlm.nih.gov/34416319/>.
304. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): <https://pubmed.ncbi.nlm.nih.gov/34092166/>
305. Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34291477/>
306. Petechiae and peeling of fingers after immunization with BNT162b2 messenger RNA (mRNA)-based COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34513435/>
307. Hepatitis C virus reactivation after COVID-19 vaccination: a case report: <https://pubmed.ncbi.nlm.nih.gov/34512037/>
308. Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: <https://pubmed.ncbi.nlm.nih.gov/34483273/>.
309. Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: <https://pubmed.ncbi.nlm.nih.gov/34513446/>
310. Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO x 1 nCov-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34474550/>
311. Reactive arthritis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34033732/>.
312. Two cases of Graves' disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants: <https://pubmed.ncbi.nlm.nih.gov/33858208/>
313. Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: <https://pubmed.ncbi.nlm.nih.gov/34015240/>
314. Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34482558/>

315. COVID-19 mRNA vaccine causing CNS inflammation: a case series: <https://pubmed.ncbi.nlm.nih.gov/34480607/>
316. Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: <https://pubmed.ncbi.nlm.nih.gov/34462647/>
317. Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34325334/>
318. Tolosa-Hunt syndrome occurring after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34513398/>
319. Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCoV-19 (Oxford-AstraZeneca): <https://pubmed.ncbi.nlm.nih.gov/34362727/>
320. Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): <https://pubmed.ncbi.nlm.nih.gov/34469919/>.
321. Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: <https://pubmed.ncbi.nlm.nih.gov/34516272/>.
322. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: <https://pubmed.ncbi.nlm.nih.gov/34512961/>
323. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34077949/>
324. Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): <https://pubmed.ncbi.nlm.nih.gov/34171435/>
325. Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: <https://pubmed.ncbi.nlm.nih.gov/34447349/>
326. Miocarditis linfocítica después de la vacunación con el vector viral COVID-19 Ad26.COV2.S: <https://pubmed.ncbi.nlm.nih.gov/34514078/>
327. Linfocitosis hemofagocítica después de la vacunación con ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34406660/>.
328. Vasculitis por IgA en paciente adulto después de la vacunación con ChadOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34509658/>
329. Un caso de vasculitis leucocitoclástica después de la vacunación con una vacuna contra el SARS-CoV2: informe del caso: <https://pubmed.ncbi.nlm.nih.gov/34196469/>.
330. Inicio / brote de psoriasis después de la vacuna ChAdOx1 nCoV-19 del virus Corona (Oxford-AstraZeneca / Covishield): informe de dos casos: <https://pubmed.ncbi.nlm.nih.gov/34350668/>
331. Exacerbación de la enfermedad de Hailey-Hailey después de la vacunación contra el SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34436620/>
332. Linfadenopatía supraclavicular tras la vacunación contra la COVID-19 en Corea: seguimiento en serie por ecografía: <https://pubmed.ncbi.nlm.nih.gov/34116295/>.
333. Vacuna COVID-19, trombocitopenia trombótica inmune, ictericia, hiperviscosidad: preocupación en casos con problemas hepáticos subyacentes: <https://pubmed.ncbi.nlm.nih.gov/34509271/>.
334. Informe del Consorcio Internacional de Trombosis Venosa Cerebral sobre trombosis venosa cerebral después de la vacunación contra el SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34462996/>
335. Trombocitopenia inmune después de la vacunación durante la pandemia de COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34435486/>
336. COVID-19: las lecciones de la tragedia noruega deben tenerse en cuenta en la planificación del lanzamiento de la vacuna en los países menos desarrollados / en desarrollo: <https://pubmed.ncbi.nlm.nih.gov/34435142/>
337. Linfólisis aguda inducida por rituximab y pancitopenia después de la vacunación con COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34429981/>
338. Exacerbación de la psoriasis en placas tras las vacunas inactivadas de ARNm y BNT162b2 por COVID-19: informe de dos casos: <https://pubmed.ncbi.nlm.nih.gov/34427024/>
339. Enfermedad pulmonar intersticial inducida por vacunación: una reacción rara a la vacuna COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34510014/>.
340. Reacciones cutáneas vesiculobullosas inducidas por la vacuna de ARNm COVID-19: informe de cuatro casos y revisión de la literatura: <https://pubmed.ncbi.nlm.nih.gov/34236711/>
341. Trombocitopenia inducida por vacunación con dolor de cabeza intenso: <https://pubmed.ncbi.nlm.nih.gov/34525282/>
342. Perimiocarditis aguda después de la primera dosis de la vacuna de ARNm contra la COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34515024/>
343. Rabdomiólisis y fascitis inducida por la vacuna de ARNm COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34435250/>.

344. Efectos adversos cutáneos raros de las vacunas contra la COVID-19: una serie de casos y revisión de la literatura: <https://pubmed.ncbi.nlm.nih.gov/34363637/>
345. Trombocitopenia inmune asociada con la vacuna de ARNm COVID-19 de Pfizer-BioNTech BNT162b2: <https://www.sciencedirect.com/science/article/pii/S2214250921002018>
346. Trombocitopenia inmune secundaria supuestamente atribuible a la vacunación contra la COVID-19: <https://casereports.bmj.com/content/14/5/e242220.abstract>.
347. Trombocitopenia inmune tras la vacuna Pfizer-BioNTech BNT162b2 mRNA COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34155844/>
348. Trombocitopenia idiopática recién diagnosticada después de la administración de la vacuna COVID-19: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/>.
349. Púrpura trombocitopénica idiopática y la vacuna moderna contra el Covid-19: [https://www.annemergmed.com/article/S0196-0644\(21\)00122-0/fulltext](https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext).
350. Trombocitopenia tras la vacunación contra el SARS de Pfizer y Moderna – CoV - 2: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/>.
351. Púrpura trombocitopénica inmune y lesión hepática aguda después de la vacunación contra covid-19: <https://casereports.bmj.com/content/14/7/e242678>.
352. Recopilación de afecciones hematológicas mediadas por complemento y autoinmunes después de la vacunación contra el SARS-CoV-2: <https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic>
353. Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: <https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794>
354. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: <https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines-induce-severe-hemolysis-in>
355. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: <https://pubmed.ncbi.nlm.nih.gov/34288044/>.
356. Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: <https://pubmed.ncbi.nlm.nih.gov/34327553/>.
357. Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33878469/>.
358. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: <https://pubmed.ncbi.nlm.nih.gov/33857630/>.
359. Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34090750/>.
360. Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34312301/>.
361. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34333995/>
362. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34455073/>
363. Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34111775/>.
364. Cerebral venous thrombosis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34045111/>
365. Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33983464/>
366. Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34116145/>
367. Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: <https://pubmed.ncbi.nlm.nih.gov/34286453/>.
368. Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: <https://pubmed.ncbi.nlm.nih.gov/34478433/>
369. Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: <https://pubmed.ncbi.nlm.nih.gov/34244448/>
370. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: <https://pubmed.ncbi.nlm.nih.gov/34226070/>
371. Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: <https://pubmed.ncbi.nlm.nih.gov/33845870/>.

372. Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34101024/>.
373. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: <https://pubmed.ncbi.nlm.nih.gov/34393988/>.
374. Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: <https://pubmed.ncbi.nlm.nih.gov/34407607/>.
375. Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: <https://pubmed.ncbi.nlm.nih.gov/34313952/>.
376. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): <https://pubmed.ncbi.nlm.nih.gov/34092166/>.
377. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: <https://pubmed.ncbi.nlm.nih.gov/34293217/>.
378. A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: <https://pubmed.ncbi.nlm.nih.gov/34274191/>.
379. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: <https://pubmed.ncbi.nlm.nih.gov/34186376/>.
380. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: <https://pubmed.ncbi.nlm.nih.gov/33952445/>.
381. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34129181/>.
382. S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: <https://pubmed.ncbi.nlm.nih.gov/33929487/>.
383. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34341358/>.
384. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: <https://pubmed.ncbi.nlm.nih.gov/34175640/>.
385. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: <https://pubmed.ncbi.nlm.nih.gov/34159588/>.
386. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): <https://pubmed.ncbi.nlm.nih.gov/34402666/>.
387. Autoimmunity roots of thrombotic events after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34508917/>.
388. Cerebral venous sinus thrombosis after vaccination: the UK experience: <https://pubmed.ncbi.nlm.nih.gov/34370974/>.
389. Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: <https://pubmed.ncbi.nlm.nih.gov/34373991/>.
390. Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34490632/>.
391. An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33909350/>.
392. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: <https://pubmed.ncbi.nlm.nih.gov/33981305/>.
393. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34272622/>.
394. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33877737/>.
395. Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34254476/>.
396. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: <https://pubmed.ncbi.nlm.nih.gov/34108714/>.



397. ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: <https://pubmed.ncbi.nlm.nih.gov/34483267/>.
398. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34261635/>
399. Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: <https://pubmed.ncbi.nlm.nih.gov/34202817/>
400. Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: <https://pubmed.ncbi.nlm.nih.gov/34273119/>
401. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34463066/>
402. A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34276917/>
403. Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34237213/>.
404. Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): <https://pubmed.ncbi.nlm.nih.gov/34268278/>.
405. Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/33990339/>.
406. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: <https://pubmed.ncbi.nlm.nih.gov/34479760/>.
407. Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: <https://pubmed.ncbi.nlm.nih.gov/34314875/>.
408. Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34384129/>
409. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: <https://pubmed.ncbi.nlm.nih.gov/34382387/>
410. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: <https://pubmed.ncbi.nlm.nih.gov/34416184/>.
411. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: <https://pubmed.ncbi.nlm.nih.gov/34261297/>
412. Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34261296/>
413. Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34250318/>.
414. A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34059191/>
415. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34189756/>
416. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34331506/>
417. Vaccine-induced thrombocytopenia with severe headache: <https://pubmed.ncbi.nlm.nih.gov/34525282/>
418. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: <https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1>
419. COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: <https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09>.
420. Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine: <https://onlinelibrary.wiley.com/doi/10.1111/trf.16672>
421. Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: <https://t.co/j0IEM8cMXI>
422. A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: <https://pubmed.ncbi.nlm.nih.gov/34601006/>

423. This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: <https://www.nejm.org/doi/full/10.1056/NEJMoa2110475>
424. Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: <https://www.sciencedirect.com/science/article/pii/S1201971221007797>
425. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: <https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1>.
426. Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: <https://www.sciencedirect.com/science/article/pii/S0168827821020936>
427. Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: <https://www.nature.com/articles/s41421-021-00329-3>
428. Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/>
429. Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution: [https://www.ahajournals.org/doi/10.1161/circ.144.suppl\\_1.10712](https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712)
430. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome: <https://www.science.org/doi/10.1126/sciadv.abl8213>
431. Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COVS.2: first documented case outside the U.S.: <https://pubmed.ncbi.nlm.nih.gov/34626338/>
432. A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: <https://europepmc.org/article/PPR/PPR304469> 435.
433. VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34731555/>
434. Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: <https://pubmed.ncbi.nlm.nih.gov/34159588/>
435. Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34461442/>
436. Spectrum of neurological complications after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34719776/>.
437. Cerebral venous sinus thrombosis after vaccination: the UK experience: <https://pubmed.ncbi.nlm.nih.gov/34370974/>
438. Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34373413/>
439. Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34598301/>
440. Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34620638/>
441. Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: <https://pubmed.ncbi.nlm.nih.gov/34650896/>
442. Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34625447/>
443. Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: <https://pubmed.ncbi.nlm.nih.gov/34696248/>
444. Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: <https://pubmed.ncbi.nlm.nih.gov/34548920/>
445. Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): <https://pubmed.ncbi.nlm.nih.gov/34672380/>.
446. Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34556531/>.
447. Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34535076/>.
448. Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34379914/>.

449. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: <https://pubmed.ncbi.nlm.nih.gov/34545400/>
450. Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34035134/>
451. In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: <https://pubmed.ncbi.nlm.nih.gov/34688190/>
452. Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: <https://pubmed.ncbi.nlm.nih.gov/34782400/>
453. Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: <https://pubmed.ncbi.nlm.nih.gov/34710832/>
454. Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: <https://pubmed.ncbi.nlm.nih.gov/34695859/>
455. Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: <https://pubmed.ncbi.nlm.nih.gov/34453762/>.
456. Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: <https://pubmed.ncbi.nlm.nih.gov/34660652/>.
457. Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: <https://pubmed.ncbi.nlm.nih.gov/34644642/>
458. Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: <https://pubmed.ncbi.nlm.nih.gov/34694650/>
459. Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34726934/>
460. Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: <https://pubmed.ncbi.nlm.nih.gov/34835237/>
461. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: <https://pubmed.ncbi.nlm.nih.gov/34261297/>
462. Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34724036/>.
463. Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA: <https://pubmed.ncbi.nlm.nih.gov/34839563/>
464. Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34783932/>.
465. COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: <https://pubmed.ncbi.nlm.nih.gov/34624910/>
466. Inflammatory myositis after vaccination with ChAdOx1: <https://pubmed.ncbi.nlm.nih.gov/34585145/>
467. Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): <https://pubmed.ncbi.nlm.nih.gov/34580132/>.
468. A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: <https://pubmed.ncbi.nlm.nih.gov/34535492/>
469. COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series: <https://pubmed.ncbi.nlm.nih.gov/34527501/>
470. Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: <https://pubmed.ncbi.nlm.nih.gov/34272095/>
471. Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: <https://pubmed.ncbi.nlm.nih.gov/34756770/>
472. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: <https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622>
473. Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34781321/>
474. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines: <https://pubmed.ncbi.nlm.nih.gov/34062319/>

475. Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: <https://pubmed.ncbi.nlm.nih.gov/34706921/>
476. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: <https://pubmed.ncbi.nlm.nih.gov/34698582/>.
477. Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34751013/>.
478. Acute transverse myelitis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34684047/>.
479. Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34541935/>
480. Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report: <https://pubmed.ncbi.nlm.nih.gov/34273119/>
481. Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: <https://pubmed.ncbi.nlm.nih.gov/34327553/>.
482. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33877737/>
483. Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34646685/>
484. Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34242687/>.
485. Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34609603/>
486. Case report: Pityriasis rosea-like rash after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34557507/>
487. Extensive longitudinal transverse myelitis after ChAdOx1 nCoV-19 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34641797/>.
488. Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222: <https://pubmed.ncbi.nlm.nih.gov/34812326/>.
489. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): <https://pubmed.ncbi.nlm.nih.gov/34006408/>
490. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: <https://pubmed.ncbi.nlm.nih.gov/34416184/>
491. Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: <https://pubmed.ncbi.nlm.nih.gov/34664303/>.
492. Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34649281/>.
493. Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34420249/>
494. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: <https://pubmed.ncbi.nlm.nih.gov/34610990/>.
495. Sweet's syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: <https://pubmed.ncbi.nlm.nih.gov/34590397/>
496. Sudden sensorineural hearing loss after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34670143/>.
497. Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: <https://pubmed.ncbi.nlm.nih.gov/34819146/>.
498. Acute hemichorea-hemiballismus after COVID-19 (AZD1222) vaccination: <https://pubmed.ncbi.nlm.nih.gov/34581453/>
499. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: <https://pubmed.ncbi.nlm.nih.gov/34741583/>
500. Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: <https://pubmed.ncbi.nlm.nih.gov/34631069/>
501. Thrombosis after COVID-19 vaccination: possible link to ACE pathways: <https://pubmed.ncbi.nlm.nih.gov/34479129/>

502. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34331506/>
503. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): <https://pubmed.ncbi.nlm.nih.gov/34546608/>
504. Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34546343/>
505. Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34849183/>
506. Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34853744/>.
507. A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): <https://pubmed.ncbi.nlm.nih.gov/34751429/>.
508. Ocular adverse events following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34559576/>
509. Depression after ChAdOx1-S / nCoV-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34608345/>.
510. Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34384129/>.
511. Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: <https://pubmed.ncbi.nlm.nih.gov/34755433/>
512. Major artery thrombosis and vaccination against ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34839830/>
513. Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: <https://pubmed.ncbi.nlm.nih.gov/34667486/>
514. Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: <https://pubmed.ncbi.nlm.nih.gov/34726187/>.
515. Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34781027/>
516. Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: <https://pubmed.ncbi.nlm.nih.gov/34595694/>
517. Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: <https://pubmed.ncbi.nlm.nih.gov/34661934/>
518. Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: [https://pubmed.ncbi.nlm.nih.gov/34788138](https://pubmed.ncbi.nlm.nih.gov/34788138/)
519. Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34753210/>.
520. Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34653943/>.
521. Relapse of immune thrombocytopenia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34591991/>
522. Thrombosis in pre- and post-vaccination phase of COVID-19; <https://pubmed.ncbi.nlm.nih.gov/34650382/>
523. A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: <https://pubmed.ncbi.nlm.nih.gov/34769454/>
524. COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: <https://pubmed.ncbi.nlm.nih.gov/34786893/>
525. Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: <https://pubmed.ncbi.nlm.nih.gov/34833382/>
526. Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): <https://pubmed.ncbi.nlm.nih.gov/34670287/>
527. An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34790811/>
528. Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-

- 19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: <https://pubmed.ncbi.nlm.nih.gov/34023956/>.
529. Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: <https://pubmed.ncbi.nlm.nih.gov/34629931/>
530. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): <https://pubmed.ncbi.nlm.nih.gov/34402666/>
531. Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34842783/>
532. Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34630307/>
533. Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33983464/>
534. Autoimmune roots of thrombotic events after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34508917/>.
535. New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: [https://www.jcehepatology.com/article/S0973-6883\(21\)00545-4/fulltext](https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext).
536. Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca® COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33962903/>.
537. Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: <https://pubmed.ncbi.nlm.nih.gov/34796065/>.
538. Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: <https://pubmed.ncbi.nlm.nih.gov/34579248/>
539. A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34843991/>
540. Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): <https://pubmed.ncbi.nlm.nih.gov/34595867/>
541. A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): <https://pubmed.ncbi.nlm.nih.gov/34820240/>
542. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton's tyrosine kinase inhibitors: <https://pubmed.ncbi.nlm.nih.gov/33851389/>
543. Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S: <https://pubmed.ncbi.nlm.nih.gov/33980419/>
544. Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34264151/>
545. Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: <https://pubmed.ncbi.nlm.nih.gov/34734086/>
546. Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: <https://pubmed.ncbi.nlm.nih.gov/34755555/>
547. Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: <https://pubmed.ncbi.nlm.nih.gov/34407607/>
548. Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34264514/>.
549. Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): <https://pubmed.ncbi.nlm.nih.gov/34840204/>
550. Neurological side effects of SARS-CoV-2 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34750810/>
551. Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: <https://pubmed.ncbi.nlm.nih.gov/34639132/>
552. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: <https://pubmed.ncbi.nlm.nih.gov/34804412/>
553. Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: <https://pubmed.ncbi.nlm.nih.gov/34571653/>.
554. Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: <https://pubmed.ncbi.nlm.nih.gov/34835275/>.
555. Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: <https://pubmed.ncbi.nlm.nih.gov/34659839/>.
556. Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series: <https://pubmed.ncbi.nlm.nih.gov/34668274/>.

557. Severe autoimmune hemolytic anemia after receiving SARS-CoV-2 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34549821/>
558. Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): <https://pubmed.ncbi.nlm.nih.gov/34528522/>
559. Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34568726/>
560. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: <https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179>.
561. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408>
562. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: <https://www.mdpi.com/2075-4426/11/11/1106>
563. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: <https://pubmed.ncbi.nlm.nih.gov/34402230/>
564. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: <https://pubmed.ncbi.nlm.nih.gov/34696294/>
565. Myocarditis Following mRNA COVID-19 Vaccine: [https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis\\_Following\\_mRNA\\_COVID\\_19\\_Vaccine.9.aspx](https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_mRNA_COVID_19_Vaccine.9.aspx).
566. Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: <https://pubmed.ncbi.nlm.nih.gov/34614328/>.
567. Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: [https://www.heartlungcirc.org/article/S1443-9506\(21\)01156-2/fulltext](https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext)
568. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34277198/>
569. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: <https://pubmed.ncbi.nlm.nih.gov/34246586/>
570. Hypersensitivity Myocarditis and COVID-19 Vaccines: <https://pubmed.ncbi.nlm.nih.gov/34856634/>.
571. Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: [https://www.internationaljournalofcardiology.com/article/S0167-5273\(21\)01477-7/fulltext](https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7/fulltext).
572. Acute myocardial infarction and myocarditis after COVID-19 vaccination: <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/>
573. Myocarditis after Covid-19 vaccination in a large healthcare organization: <https://www.nejm.org/doi/10.1056/NEJMoa2110737>
574. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: <https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052>
575. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: [https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url\\_ver=Z39.88-2003&rfr\\_id=ori:rid:crossref.org&rfr\\_dat=cr\\_pub%20%20pubmed](https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed)
576. STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination.: <https://pubmed.ncbi.nlm.nih.gov/34756746/>
577. Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/>
578. Myocarditis after COVID-19 mRNA vaccines: <https://pubmed.ncbi.nlm.nih.gov/34546329/>.
579. Patients with acute myocarditis after COVID-19 mRNA vaccination.: <https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602>.
580. Myocarditis after COVID-19 vaccination: a case series: <https://www.sciencedirect.com/science/article/pii/S0264410X21011725?via%3Dihub>.
581. Myocarditis associated with COVID-19 vaccination in adolescents: <https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357>
582. Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents.: <https://pubmed.ncbi.nlm.nih.gov/34704459/>
583. Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: <https://academic.oup.com/ehjcmimaging/advance-article/doi/10.1093/ehjci/jeab230/6421640>.

584. Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/>
585. Myocarditis after COVID-19 vaccination: <https://www.sciencedirect.com/science/article/pii/S2352906721001603>
586. Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: <https://pubmed.ncbi.nlm.nih.gov/34712717/>.
587. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: <https://www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administration-bnt162b2-S188558572100133X>.
588. Myocarditis associated with COVID-19 mRNA vaccination: <https://pubs.rsna.org/doi/10.1148/radiol.2021211430>
589. Acute myocarditis after COVID-19 vaccination: a case report: <https://www.sciencedirect.com/science/article/pii/S0248866321007098>
590. Acute myopericarditis after COVID-19 vaccination in adolescents: <https://pubmed.ncbi.nlm.nih.gov/34589238/>.
591. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination: <https://academic.oup.com/jpids/article/10/10/962/6329543>.
592. Acute myocarditis associated with anti-COVID-19 vaccination: <https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196>.
593. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings: <https://pubmed.ncbi.nlm.nih.gov/34428917/>.
594. Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34088762/>.
595. Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines: <https://academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/6442104>.
596. COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis: <https://www.mdpi.com/2036-7503/13/3/61>.
597. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: <https://pubmed.ncbi.nlm.nih.gov/34402228/>
598. Myocarditis temporally associated with COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34133885/>
599. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: <https://pubmed.ncbi.nlm.nih.gov/34219532/>
600. Acute myocarditis associated with COVID-19 vaccination: report of a case: <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/>
601. Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: <https://pubmed.ncbi.nlm.nih.gov/34840235/>.
602. Myocarditis in the setting of a recent COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34712497/>.
603. Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: [https://www.clinicalimaging.org/article/S0899-7071\(21\)00265-5/fulltext](https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext).
604. Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34568726/>
605. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: <https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179>
606. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408>.
607. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: <https://www.mdpi.com/2075-4426/11/11/1106>
608. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: <https://pubmed.ncbi.nlm.nih.gov/34402230/>



609. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: <https://pubmed.ncbi.nlm.nih.gov/34696294/>
610. Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34615534/>
611. Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34352418/>
612. Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCoV-19; <https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340>.
613. COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: <https://pubmed.ncbi.nlm.nih.gov/34632750/>
614. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia: <https://haematologica.org/article/view/haematol.2021.279075>
615. COVID-19 vaccine-induced thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34802488/>.
616. Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34887867/>.
617. Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34863404/>.
618. Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-AstraZeneca COVID-19: a missed opportunity for rapid return on experience: <https://www.sciencedirect.com/science/article/pii/S235255682100093X>
619. Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34876440/>
620. Deep venous thrombosis more than two weeks after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33928773/>
621. Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: <https://pubmed.ncbi.nlm.nih.gov/34880826/>
622. Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34587242/>
623. Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: <https://pubmed.ncbi.nlm.nih.gov/34868465/>
624. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): <https://pubmed.ncbi.nlm.nih.gov/34097311/>
625. Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: <https://pubmed.ncbi.nlm.nih.gov/34820232/>.
626. Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic portosystemic shunt and thrombectomy: <https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258>
627. Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: <https://pubmed.ncbi.nlm.nih.gov/34579636/>
628. Successful treatment of vaccine-induced immune thrombotic thrombocytopenia in a 26-year-old female patient: <https://pubmed.ncbi.nlm.nih.gov/34614491/>
629. Case report: vaccine-induced immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: <https://pubmed.ncbi.nlm.nih.gov/34790684/>
630. Idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): <https://pubmed.ncbi.nlm.nih.gov/33624509/>.
631. Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): <https://pubmed.ncbi.nlm.nih.gov/34612003/>
632. Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: <https://pubmed.ncbi.nlm.nih.gov/34096082/>
633. Myocarditis associated with COVID-19 vaccination in three adolescent boys: <https://pubmed.ncbi.nlm.nih.gov/34851078/>.
634. Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: <https://pubmed.ncbi.nlm.nih.gov/34496880/>
635. Perimyocarditis after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34866957/>

636. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: <https://pubmed.ncbi.nlm.nih.gov/34849657/>.
637. Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: <https://pubmed.ncbi.nlm.nih.gov/34664804/>
638. Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: <https://pubmed.ncbi.nlm.nih.gov/34605853/>
639. Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: <https://pubmed.ncbi.nlm.nih.gov/34166671/>
640. Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: <https://pubmed.ncbi.nlm.nih.gov/34744118/>
641. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: <https://pubmed.ncbi.nlm.nih.gov/34334935/>.
642. Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34746968/>
643. Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?": <https://pubmed.ncbi.nlm.nih.gov/34333695/>.
644. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34180390/>
645. Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: <https://pubmed.ncbi.nlm.nih.gov/34185045/>
646. Myocarditis after BNT162b2 vaccination in a healthy male: <https://pubmed.ncbi.nlm.nih.gov/34229940/>
647. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: <https://pubmed.ncbi.nlm.nih.gov/34133825/>
648. Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: <https://pubmed.ncbi.nlm.nih.gov/34308326/>.
649. Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: <https://pubmed.ncbi.nlm.nih.gov/34866106/>
650. Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: <https://pubmed.ncbi.nlm.nih.gov/34487236/>
651. Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: <https://pubmed.ncbi.nlm.nih.gov/34848416/>
652. Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: <https://pubmed.ncbi.nlm.nih.gov/34636504/>
653. Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: <https://pubmed.ncbi.nlm.nih.gov/34367386/>
654. Acute myocarditis in a young adult two days after vaccination with Pfizer: <https://pubmed.ncbi.nlm.nih.gov/34709227/>
655. Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: <https://pubmed.ncbi.nlm.nih.gov/34778411/>
656. Acute myocarditis after 2019 coronavirus disease vaccination: <https://pubmed.ncbi.nlm.nih.gov/34734821/>
657. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: <https://pubmed.ncbi.nlm.nih.gov/34246585/>
658. Myopericarditis after Pfizer messenger ribonucleic acid coronavirus disease vaccine in adolescents: <https://pubmed.ncbi.nlm.nih.gov/34228985/>
659. Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: <https://pubmed.ncbi.nlm.nih.gov/34852213/>
660. Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease: <https://pubmed.ncbi.nlm.nih.gov/34866122/>
661. Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34601566/>
662. Myocarditis following COVID-19 vaccination: MRI study: <https://pubmed.ncbi.nlm.nih.gov/34739045/>.

663. Acute myocarditis after COVID-19 vaccination: case report: [https://docs.google.com/document/d/1Hc4bh\\_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e](https://docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e)
664. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children: <https://pubmed.ncbi.nlm.nih.gov/34374740/>
665. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: <https://pubmed.ncbi.nlm.nih.gov/34865500/>
666. Myocarditis following vaccination with Covid-19 in a large healthcare organization: <https://pubmed.ncbi.nlm.nih.gov/34614329/>
667. AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link: <https://pubmed.ncbi.nlm.nih.gov/34560365/>
668. COVID-19, Guillain-Barré and vaccineA dangerous mix: <https://pubmed.ncbi.nlm.nih.gov/34108736/>.
669. Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: <https://pubmed.ncbi.nlm.nih.gov/34796417/>.
670. Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: <https://link.springer.com/article/10.1007%2Fs10072-021-05523-5>.
671. COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy: <https://onlinelibrary.wiley.com/doi/10.1002/ana.26258>.
672. Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021: <https://jamanetwork.com/journals/jama/fullarticle/2785009>
673. A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34567447/>
674. Guillain-Barré syndrome associated with COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34648420/>.
675. Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine: <https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708>
676. Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: [https://www.pedneur.com/article/S0887-8994\(21\)00221-6/fulltext](https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext).
677. Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34114256/>.
678. Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34767184/>.
679. Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: <https://pubmed.ncbi.nlm.nih.gov/34644738/>.
680. Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: <https://pubmed.ncbi.nlm.nih.gov/34649856/>
681. A rare case of Guillain-Barré syndrome after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34671572/>
682. Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33758714/>
683. COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: <https://pubmed.ncbi.nlm.nih.gov/34484780/>
684. Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report; <https://pubmed.ncbi.nlm.nih.gov/34779385/>.
685. Miller Fisher syndrome after Pfizer COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34817727/>.
686. Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination: <https://pubmed.ncbi.nlm.nih.gov/34789193/>.
687. Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34261746/>
688. Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: <https://pubmed.ncbi.nlm.nih.gov/34217513/>.
689. A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): <https://pubmed.ncbi.nlm.nih.gov/34871447/>
690. Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in Vigibase: <https://pubmed.ncbi.nlm.nih.gov/34579259/>
691. A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: <https://pubmed.ncbi.nlm.nih.gov/34370408/>.

692. A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S: <https://pubmed.ncbi.nlm.nih.gov/34703690/>.
693. Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: <https://pubmed.ncbi.nlm.nih.gov/34810163/>
694. Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: <https://onlinelibrary.wiley.com/doi/10.1002/ana.26218>.
695. Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34482455/>.
696. Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34114269/>.
697. Guillain-Barré syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: <https://pubmed.ncbi.nlm.nih.gov/34722067/>
698. Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: <https://pubmed.ncbi.nlm.nih.gov/33968610/>
699. SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: <https://pubmed.ncbi.nlm.nih.gov/34525410/>
700. Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: <https://pubmed.ncbi.nlm.nih.gov/34808658/>
701. Adverse event reporting and risk of Bell's palsy after COVID-19 vaccination: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(21\)00646-0/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/fulltext).
702. Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: <https://pubmed.ncbi.nlm.nih.gov/34522557/>
703. Left Bell's palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34763263/>.
704. Bell's palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell's palsy: case report: <https://pubmed.ncbi.nlm.nih.gov/34621891/>
705. Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: <https://pubmed.ncbi.nlm.nih.gov/34697502/>
706. Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell's palsy: <https://pubmed.ncbi.nlm.nih.gov/33858693/>
707. Acute transverse myelitis following inactivated COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34370410/>
708. Acute transverse myelitis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34579245/>.
709. A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34182207/>
710. Post COVID-19 transverse myelitis; a case report with review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34457267/>.
711. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34189662/>
712. Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: <https://pubmed.ncbi.nlm.nih.gov/34660149/>
713. Acute bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34131771/>
714. A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: <https://pubmed.ncbi.nlm.nih.gov/34635376/>
715. Acute pericarditis and cardiac tamponade after vaccination with Covid-19: <https://pubmed.ncbi.nlm.nih.gov/34749492/>
716. Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: <https://pubmed.ncbi.nlm.nih.gov/34849667/>
717. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34319393/>
718. Acute myopericarditis after COVID-19 vaccine in adolescents: <https://pubmed.ncbi.nlm.nih.gov/34589238/>
719. Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34149145/>
720. Case report: symptomatic pericarditis post COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34693198/>.

721. An outbreak of Still's disease after COVID-19 vaccination in a 34-year-old patient: <https://pubmed.ncbi.nlm.nih.gov/34797392/>
722. Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): <https://pubmed.ncbi.nlm.nih.gov/34862234/>
723. Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: <https://pubmed.ncbi.nlm.nih.gov/34396358/>.
724. Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34848426/>.
725. Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/33946748/>
726. Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34591186/>
727. Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34352309/>
728. Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: <https://pubmed.ncbi.nlm.nih.gov/34804803/>.
729. Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: <https://pubmed.ncbi.nlm.nih.gov/34077572/>
730. Retinal hemorrhage after SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34884407/>.
731. Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34859017/>
732. Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: <https://pubmed.ncbi.nlm.nih.gov/34783899/>
733. Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34549178/>.
734. Brain death in a vaccinated patient with COVID-19 infection: <https://pubmed.ncbi.nlm.nih.gov/34656887/>
735. Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination: <https://pubmed.ncbi.nlm.nih.gov/34236717/>.
736. Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34729467/>.
737. A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33932458/>
738. Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: <https://pubmed.ncbi.nlm.nih.gov/34092400/742>.
739. Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34754937/>
740. Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: <https://pubmed.ncbi.nlm.nih.gov/33771584/>
741. Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34846583/>
742. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: <https://pubmed.ncbi.nlm.nih.gov/34073536/>
743. Bell's palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: <https://pubmed.ncbi.nlm.nih.gov/34411532/>
744. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval: <https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1>
745. Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: <https://pubmed.ncbi.nlm.nih.gov/33851711/>
746. Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: <https://pubmed.ncbi.nlm.nih.gov/34675550/>.
747. Anaphylaxis after Modern COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34734159/>.
748. Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34698847/>
749. Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34020815/>

750. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: <https://pubmed.ncbi.nlm.nih.gov/33641264/>
751. Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: <https://pubmed.ncbi.nlm.nih.gov/33641268/>
752. Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: <https://pubmed.ncbi.nlm.nih.gov/33834172/>
753. Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: <https://pubmed.ncbi.nlm.nih.gov/34579211/>
754. Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: <https://pubmed.ncbi.nlm.nih.gov/34343674/>
755. Acute myocardial infarction and myocarditis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34586408/>
756. Takotsubo syndrome after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34539938/>.
757. Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: <https://pubmed.ncbi.nlm.nih.gov/34731486/>.
758. Premature myocardial infarction or side effect of COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33824804/>
759. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: <https://pubmed.ncbi.nlm.nih.gov/34807248/>
760. Kounis syndrome type 1 induced by inactivated SARS-CoV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34148772/>
761. Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit: <https://pubmed.ncbi.nlm.nih.gov/34702550/>
762. Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty®): <https://pubmed.ncbi.nlm.nih.gov/33895650/>
763. Deaths associated with recently launched SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34425384/>
764. A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: <https://pubmed.ncbi.nlm.nih.gov/34703815/>
765. COVID-19 vaccine-induced urticarial vasculitis: <https://pubmed.ncbi.nlm.nih.gov/34369046/>.
766. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34280507/>.
767. New-onset leukocytoclastic vasculitis after COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34241833/>
768. Cutaneous small vessel vasculitis after COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34529877/>.
769. Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33928638/>
770. Leukocytoclastic vasculitis after exposure to COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34836739/>
771. Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?; <https://pubmed.ncbi.nlm.nih.gov/34495381/>.
772. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34327795/>
773. Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34660867/>.
774. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Immune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: <https://pubmed.ncbi.nlm.nih.gov/34659268/>
775. Reactivation of IgA vasculitis after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34848431/>
776. Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34310759/>.
777. Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: <https://pubmed.ncbi.nlm.nih.gov/34720009/>

778. A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34518812/>
779. Cutaneous vasculitis following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34611627/>.
780. Posible caso de vasculitis de vasos pequeños inducida por la vacuna de ARNm COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34705320/>.
781. Vasculitis por IgA después de la vacunación contra la COVID-19 en un adulto: <https://pubmed.ncbi.nlm.nih.gov/34779011/>
782. Vasculitis asociada a anticuerpos citoplasmáticos antinutróficos inducida por propiltiouracilo después de la vacunación con COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34451967/>
783. Vacuna contra la enfermedad por coronavirus 2019 (COVID-19) en la vasculitis asociada al lupus eritematoso sistémico y anticuerpos anticitoplasmáticos de neutrófilos: <https://pubmed.ncbi.nlm.nih.gov/33928459/>
784. Reactivación de la vasculitis por IgA tras la vacunación contra la COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34250509/>
785. Espectro clínico e histopatológico de reacciones cutáneas adversas retardadas después de la vacunación contra la COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34292611/>.
786. Primera descripción de la vasculitis del complejo inmunitario después de la vacunación contra la COVID-19 con BNT162b2: informe del caso: <https://pubmed.ncbi.nlm.nih.gov/34530771/>.
787. Síndrome nefrótico y vasculitis tras la vacuna contra el SARS-CoV-2: asociación verdadera o circunstancial: <https://pubmed.ncbi.nlm.nih.gov/34245294/>.
788. Aparición de vasculitis cutánea de novo después de la vacunación contra la enfermedad por coronavirus (COVID-19): <https://pubmed.ncbi.nlm.nih.gov/34599716/>.
789. Vasculitis cutánea asimétrica después de la vacunación contra la COVID-19 con preponderancia inusual de eosinófilos: <https://pubmed.ncbi.nlm.nih.gov/34115904/>.
790. Púrpura de Henoch-Schönlein que ocurre después de la vacunación con COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34247902/>.
791. Púrpura de Henoch-Schönlein después de la primera dosis de la vacuna contra vectores virales COVID-19: informe de caso: <https://pubmed.ncbi.nlm.nih.gov/34696186/>.
792. Vasculitis granulomatosa después de la vacuna anti-SARS-CoV-2 de AstraZeneca: <https://pubmed.ncbi.nlm.nih.gov/34237323/>.
793. Necrosis retiniana aguda por reactivación del virus de la varicela zóster tras la vacunación con ARNm BNT162b2 COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34851795/>.
794. Un caso de síndrome de Sweet generalizado con vasculitis desencadenado por la reciente vacunación con COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34849386/>
795. Vasculitis de vasos pequeños tras la vacunación de Oxford-AstraZeneca contra el SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34310763/>
796. Recaída de poliangeítis microscópica después de la vacunación contra la COVID-19: informe de caso: <https://pubmed.ncbi.nlm.nih.gov/34251683/>.
797. Vasculitis cutánea después de la vacuna contra el coronavirus 2 del síndrome respiratorio agudo grave: <https://pubmed.ncbi.nlm.nih.gov/34557622/>.
798. Herpes zóster recurrente después de la vacunación contra el COVID-19 en pacientes con urticaria crónica en tratamiento con ciclosporina – Un informe de 3 casos: <https://pubmed.ncbi.nlm.nih.gov/34510694/>
799. Vasculitis leucocitoclástica después de la vacunación contra la enfermedad por coronavirus 2019: <https://pubmed.ncbi.nlm.nih.gov/34713472/803>
800. Brotes de vasculitis por crioglobulinemia mixta después de la vacunación contra el SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34819272/>
801. Vasculitis cutánea de vasos pequeños después de la vacunación con una dosis única de Janssen Ad26.COV2.S: <https://pubmed.ncbi.nlm.nih.gov/34337124/>
802. Caso de vasculitis por inmunoglobulina A tras la vacunación contra la enfermedad por coronavirus 2019: <https://pubmed.ncbi.nlm.nih.gov/34535924/>
803. Progresión rápida del linfoma angioinmunoblástico de células T después de la vacunación de refuerzo con ARNm BNT162b2: informe de caso: <https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/>
804. La linfadenopatía inducida por la vacunación con ARNm covid-19 imita la progresión del linfoma en FDG PET / CT: <https://pubmed.ncbi.nlm.nih.gov/33591026/>
805. Linfadenopatía en receptores de la vacuna COVID-19: dilema diagnóstico en pacientes oncológicos: <https://pubmed.ncbi.nlm.nih.gov/33625300/>

806. Linfadenopatía hipermetabólica después de la administración de la vacuna BNT162b2 mRNA Covid-19: incidencia evaluada por [ 18 F] FDG PET-CT y relevancia para la interpretación del estudio: <https://pubmed.ncbi.nlm.nih.gov/33774684/>
807. Linfadenopatía después de la vacunación contra la COVID-19: revisión de los hallazgos de la imagen: <https://pubmed.ncbi.nlm.nih.gov/33985872/>
808. Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34735411/>
809. Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: <https://pubmed.ncbi.nlm.nih.gov/34115709/>.
810. COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: <https://pubmed.ncbi.nlm.nih.gov/34257025/>.
811. COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: <https://pubmed.ncbi.nlm.nih.gov/34836672/>.
812. Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: <https://pubmed.ncbi.nlm.nih.gov/34280870/>
813. COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings: <https://pubmed.ncbi.nlm.nih.gov/34432391/>
814. Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: <https://pubmed.ncbi.nlm.nih.gov/34731748/>
815. Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: <https://pubmed.ncbi.nlm.nih.gov/34906409/>
816. Adverse events of COVID injection that may occur in children. Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: <https://pubmed.ncbi.nlm.nih.gov/33706861/>
817. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: <https://pubmed.ncbi.nlm.nih.gov/34116295/>
818. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: <https://pubmed.ncbi.nlm.nih.gov/33661328/>
819. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34050949/>
820. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: <https://pubmed.ncbi.nlm.nih.gov/33624520/>
821. A case of cervical lymphadenopathy following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34141500/>
822. Unique imaging findings of neurologic phantasmia after Pfizer-BioNTech COVID-19 vaccination: a case report: <https://pubmed.ncbi.nlm.nih.gov/34096896/>
823. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: <https://pubmed.ncbi.nlm.nih.gov/34835256/>
824. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: <https://pubmed.ncbi.nlm.nih.gov/33713605/>
825. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: <https://pubmed.ncbi.nlm.nih.gov/34298342/>
826. A systematic review of cases of CNS demyelination following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34839149/>
827. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: <https://pubmed.ncbi.nlm.nih.gov/33685772/>
828. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: <https://pubmed.ncbi.nlm.nih.gov/34719892/>
829. Adenopathy after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33625299/>.
830. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34292295/>.



831. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: <https://pubmed.ncbi.nlm.nih.gov/33947605/>.
832. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: <https://pubmed.ncbi.nlm.nih.gov/34526175/>
833. Lymphadenopathy associated with the COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33786231/>
834. Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33625301/>.
835. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34332438/>.
836. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: <https://pubmed.ncbi.nlm.nih.gov/34342187/>.
837. Massive cervical lymphadenopathy following vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34601889/>
838. ANCA glomerulonephritis following Modern COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34081948/>
839. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34507942/>.
840. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCoV-19 (Oxford-AstraZeneca): <https://pubmed.ncbi.nlm.nih.gov/34362727/>
841. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: <https://pubmed.ncbi.nlm.nih.gov/34325221/>
842. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: <https://pubmed.ncbi.nlm.nih.gov/34825530/>.
843. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34000278/>
844. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: <https://pubmed.ncbi.nlm.nih.gov/34655312/>.
845. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34187985/>.
846. Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: <https://pubmed.ncbi.nlm.nih.gov/33706861/>
847. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: <https://pubmed.ncbi.nlm.nih.gov/34116295/>
848. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: <https://pubmed.ncbi.nlm.nih.gov/33661328/>
849. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34050949/>
850. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: <https://pubmed.ncbi.nlm.nih.gov/33624520/>
851. A case of cervical lymphadenopathy following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34141500/>
852. Unique imaging findings of neurologic phantasmia after Pfizer-BioNTech COVID-19 vaccination: a case report: <https://pubmed.ncbi.nlm.nih.gov/34096896/>
853. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: <https://pubmed.ncbi.nlm.nih.gov/34835256/>
854. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: <https://pubmed.ncbi.nlm.nih.gov/33713605/>
855. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: <https://pubmed.ncbi.nlm.nih.gov/34298342/>
856. A systematic review of cases of CNS demyelination following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34839149/>
857. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: <https://pubmed.ncbi.nlm.nih.gov/33685772/>
858. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: <https://pubmed.ncbi.nlm.nih.gov/34719892/>

859. Adenopathy after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33625299/>.
860. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34292295/>.
861. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: <https://pubmed.ncbi.nlm.nih.gov/33947605/>.
862. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: <https://pubmed.ncbi.nlm.nih.gov/34526175/>
863. Lymphadenopathy associated with the COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33786231/>
864. Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33625301/>.
865. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34332438/>.
866. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: <https://pubmed.ncbi.nlm.nih.gov/34342187/>.
867. Massive cervical lymphadenopathy following vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34601889/>
868. ANCA glomerulonephritis following Modern COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34081948/>
869. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34507942/>.
870. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCoV-19 (Oxford-AstraZeneca): <https://pubmed.ncbi.nlm.nih.gov/34362727/>
871. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: <https://pubmed.ncbi.nlm.nih.gov/34325221/>
872. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: <https://pubmed.ncbi.nlm.nih.gov/34825530/>.
873. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34000278/>
874. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: <https://pubmed.ncbi.nlm.nih.gov/34655312/>.
875. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34187985/>.
876. Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. *Int J Cardiol*, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. <https://www.ncbi.nlm.nih.gov/pubmed/34416319>
877. Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. *Vaccine*, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. <https://www.ncbi.nlm.nih.gov/pubmed/34092429>
878. Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. *Radiol Case Rep*, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. <https://www.ncbi.nlm.nih.gov/pubmed/34025885>
879. Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. *QJM*. doi:10.1093/qjmed/hcab252. <https://www.ncbi.nlm.nih.gov/pubmed/34586408>
880. Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. *J Emerg Med*, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. <https://www.ncbi.nlm.nih.gov/pubmed/34756746>
881. Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *N Engl J Med*, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475. <https://www.ncbi.nlm.nih.gov/pubmed/34432976>
882. Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus y manifestaciones cardiovasculares: llegar al meollo del asunto. *Mundo J Cardiol*, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. <https://www.ncbi.nlm.nih.gov/pubmed/34754400>
883. Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Miocarditis con vacunas de ARNm COVID-19. *Circulación*, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. <https://www.ncbi.nlm.nih.gov/pubmed/34281357>

884. Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Liberación de autoanticuerpos en niños después de la vacunación con ARNm del virus Corona: ¿un factor de riesgo del síndrome inflamatorio multisistémico? *Vacunas (Basilea)*, 9(11). doi:10.3390/vaccines9111353. <https://www.ncbi.nlm.nih.gov/pubmed/34835284>
885. Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Sobre el inesperado estado protrombótico tras algunas vacunas contra la enfermedad por coronavirus 2019. *J Cardiovasc Med (Hagerstown)*, 23(2), 71-74. doi:10.2459/JCM.0000000000001232. <https://www.ncbi.nlm.nih.gov/pubmed/34366403>
886. Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). Vacuna COVID 19 para adolescentes. Preocupación por la miocarditis y la pericarditis. *Pediatr Rep*, 13(3), 530-533. doi:10.3390/pediátrico13030061. <https://www.ncbi.nlm.nih.gov/pubmed/34564344>
887. Chai, Q., Nygaard, U., Schmidt, R.C., Zaremba, T., Moller, A.M., & Thorvig, C.M. (2022). Síndrome inflamatorio multisistémico en un adolescente masculino después de su segunda vacuna Pfizer-BioNTech COVID-19. *Acta Paediatr*, 111(1), 125-127. doi:10.1111/apa.16141. <https://www.ncbi.nlm.nih.gov/pubmed/34617315>
888. Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Aparición de miocarditis aguda similar a un infarto después de la vacunación contra la COVID-19: ¿solo una coincidencia accidental o más bien una miocarditis autoinmune asociada a la vacunación? *Clin Res Cardiol*, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. <https://www.ncbi.nlm.nih.gov/pubmed/34333695>
889. Chang, J.C., & Hawley, H.B. (2021). Trombocitopenia y trombosis asociadas a la vacuna: endotelopatía venosa que conduce a microrromtrombosis venosa combinada. *Medicina (Kaunas)*, 57(11). doi:10.3390/medicina57111163. <https://www.ncbi.nlm.nih.gov/pubmed/34833382>
890. Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Hallazgos de resonancia magnética cardíaca de miocarditis después de la vacunación con ARNm de COVID-19 en adolescentes. *AJR Am J Roentgenol*. doi:10.2214/AJR.21.26853. <https://www.ncbi.nlm.nih.gov/pubmed/34704459>
891. Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Muerte súbita inducida por miocarditis después de la vacunación contra el COVID-19 con ARNm BNT162b2 en Corea: informe de caso centrado en hallazgos histopatológicos. *J Korean Med Sci*, 36(40), e286. doi:10.3346/jkms.2021.36.e286. <https://www.ncbi.nlm.nih.gov/pubmed/34664804>
892. Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Características de las reacciones cardíacas inflamatorias después de la vacunación con ARNm contra la COVID-19 a nivel mundial. *Clin Pharmacol Ther*. doi:10.1002/cpt.2499. <https://www.ncbi.nlm.nih.gov/pubmed/34860360>
893. Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E.C., Tian, T., . . . Ip, P. (2021). Epidemiología de la miocarditis/pericarditis aguda en adolescentes de Hong Kong después de la vacunación contra comirnaty. *Clin Infect Dis*. doi:10.1093/cid/ciab989. <https://www.ncbi.nlm.nih.gov/pubmed/34849657>
894. Clarke, R., & Ioannou, A. (2021). ¿Se debe utilizar el mapeo T2 en casos de miocarditis recurrente para diferenciar entre la inflamación aguda y la cicatriz crónica? *J Pediatr*. doi:10.1016/j.jpeds.2021.12.026. <https://www.ncbi.nlm.nih.gov/pubmed/34933012>
895. Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). Vacunación contra el COVID y exacerbación del asma: ¿podría haber un vínculo? *Int J Infect Dis*, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. <https://www.ncbi.nlm.nih.gov/pubmed/34547487>
896. Das, B.B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Miopericarditis después de la enfermedad por coronavirus de ARN mensajero 2019 Vacunación en adolescentes de 12 a 18 años de edad. *J Pediatr*, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. <https://www.ncbi.nlm.nih.gov/pubmed/34339728>
897. Das, B.B., Moskowitz, W.B., Taylor, M.B., & Palmer, A. (2021). Miocarditis y pericarditis después de la vacunación de ARNm contra el COVID-19: ¿Qué sabemos hasta ahora? *Niños (Basilea)*, 8(7). doi:10.3390/niños8070607. <https://www.ncbi.nlm.nih.gov/pubmed/34356586>
898. Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Lesión miocárdica aguda después de la vacunación contra covid-19: un informe de caso y revisión de la evidencia actual de la base de datos del sistema de notificación de eventos adversos de vacunas. *J Prim Care Community Health*, 12 años, 21501327211029230. doi:10.1177/21501327211029230. <https://www.ncbi.nlm.nih.gov/pubmed/34219532>

899. Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. *JACC Cardiovasc Imaging*, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. <https://www.ncbi.nlm.nih.gov/pubmed/34246585>
900. Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. *Arthritis Rheumatol*. doi:10.1002/art.41977. <https://www.ncbi.nlm.nih.gov/pubmed/34492161>
901. Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. *Ann Rheum Dis*. doi:10.1136/annrheumdis-2021-221607. <https://www.ncbi.nlm.nih.gov/pubmed/34844930>
902. Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. *Clin Res Cardiol*, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. <https://www.ncbi.nlm.nih.gov/pubmed/34487236>
903. El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J Med*, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. <https://www.ncbi.nlm.nih.gov/pubmed/34551225>
904. Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. *G Ital Cardiol (Rome)*, 22(11), 891-893. doi:10.1714/3689.36746. <https://www.ncbi.nlm.nih.gov/pubmed/34709227>
905. Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. *Rev Med Virol*, e2318. doi:10.1002/rmv.2318. <https://www.ncbi.nlm.nih.gov/pubmed/34921468>
906. Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. *Nat Commun*, 12(1), 6844. doi:10.1038/s41467-021-27120-y. <https://www.ncbi.nlm.nih.gov/pubmed/34824230>
907. Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. *Clinical research in cardiology: official journal of the German Cardiac Society*, 1-9. Advance online publication. <https://doi.org/10.1007/s00392-020-01704-y>. *Clin Res Cardiol*, 110(8), 1352. doi:10.1007/s00392-021-01896-x. <https://www.ncbi.nlm.nih.gov/pubmed/34170372>
908. Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. *Eur Heart J Qual Care Clin Outcomes*. doi:10.1093/ehjqcc/qcab090. <https://www.ncbi.nlm.nih.gov/pubmed/34849667>
909. Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. *Front Immunol*, 12, 728021. doi:10.3389/fimmu.2021.728021. <https://www.ncbi.nlm.nih.gov/pubmed/34646267>
910. Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. *Ann Rheum Dis*, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. <https://www.ncbi.nlm.nih.gov/pubmed/34127481>
911. Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. *Pediatr Clin North Am*, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004. <https://www.ncbi.nlm.nih.gov/pubmed/34538306>
912. Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from

the Advisory Committee on Immunization Practices – United States, June 2021. *MMWR Morb Mortal Wkly Rep*, 70(27), 977-982.

doi:10.15585/mmwr.mm7027e2. <https://www.ncbi.nlm.nih.gov/pubmed/34237049>

913. Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. *Vaccines (Basel)*, 9(1). doi:10.3390/vaccines9010019. <https://www.ncbi.nlm.nih.gov/pubmed/33406694>
914. Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al'Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. *Cureus*, 13(9), e17890. doi:10.7759/cureus.17890. <https://www.ncbi.nlm.nih.gov/pubmed/34660088>
915. Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. *BMJ*, 375, n3090. doi:10.1136/bmj.n3090. <https://www.ncbi.nlm.nih.gov/pubmed/34916217>
916. Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. *J Allergy Clin Immunol Pract*, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. <https://www.ncbi.nlm.nih.gov/pubmed/34153517>
917. Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. *Swiss Med Wkly*, 151, w30087. doi:10.4414/smw.2021.w30087. <https://www.ncbi.nlm.nih.gov/pubmed/34668687>
918. Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. *BMC Cardiovasc Disord*, 21(1), 375. doi:10.1186/s12872-021-02183-3. <https://www.ncbi.nlm.nih.gov/pubmed/34348657>
919. Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14, 2020-July 16, 2021. *MMWR Morb Mortal Wkly Rep*, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. <https://www.ncbi.nlm.nih.gov/pubmed/34351881>
920. Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. *J Blood Med*, 12, 221-224. doi:10.2147/JBM.S307047. <https://www.ncbi.nlm.nih.gov/pubmed/33854395>
921. Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. *BMJ*, 374, n1931. doi:10.1136/bmj.n1931. <https://www.ncbi.nlm.nih.gov/pubmed/34446426>
922. Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. *Singapore Med J*. doi:10.11622/smedj.2021210. <https://www.ncbi.nlm.nih.gov/pubmed/34808708>
923. Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. *Drug Saf*, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9. <https://www.ncbi.nlm.nih.gov/pubmed/34347278>
924. In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021). *Med Lett Drugs Ther*, 63(1629), e9. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/34544112><https://www.ncbi.nlm.nih.gov/pubmed/3454412>
925. Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. *QJM*. doi:10.1093/qjmed/hcab231. <https://www.ncbi.nlm.nih.gov/pubmed/34463755>
926. Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. *QJM*. doi:10.1093/qjmed/hcab326. <https://www.ncbi.nlm.nih.gov/pubmed/34931681>
927. Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. *Radiology*, 301(1), E378-E379. doi:10.1148/radiol.2021211766. <https://www.ncbi.nlm.nih.gov/pubmed/34342500>
928. Istampoulouglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koehlin, S., . . . Leuppi-Taegtmeier, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination:

- cases from a regional pharmacovigilance centre. *Glob Cardiol Sci Pract*, 2021(3), e202118. doi:10.21542/gcsp.2021.18. <https://www.ncbi.nlm.nih.gov/pubmed/34805376>
929. Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. *Viruses*, 13(11). doi:10.3390/v13112177. <https://www.ncbi.nlm.nih.gov/pubmed/34834983>
930. Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. *Pediatrics*, 148(5). doi:10.1542/peds.2021-053427. <https://www.ncbi.nlm.nih.gov/pubmed/34389692>
931. Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. *J Pediatric Infect Dis Soc*, 10(10), 937-939. doi:10.1093/jpids/piab061. <https://www.ncbi.nlm.nih.gov/pubmed/34270752>
932. Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). *Circ J*. doi:10.1253/circj.CJ-21-0818. <https://www.ncbi.nlm.nih.gov/pubmed/34744118>
933. Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. *Int J Cardiol Heart Vasc*, 36, 100872. doi:10.1016/j.ijcha.2021.100872. <https://www.ncbi.nlm.nih.gov/pubmed/34568540>
934. Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. *Cureus*, 13(7), e16590. doi:10.7759/cureus.16590. <https://www.ncbi.nlm.nih.gov/pubmed/34447639>
935. Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. *JAMA Cardiol*, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828. <https://www.ncbi.nlm.nih.gov/pubmed/34185046>
936. Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. *J Korean Med Sci*, 36(32), e229. doi:10.3346/jkms.2021.36.e229. <https://www.ncbi.nlm.nih.gov/pubmed/34402228>
937. King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. *Am Heart J Plus*, 8, 100042. doi:10.1016/j.ahjo.2021.100042. <https://www.ncbi.nlm.nih.gov/pubmed/34396358>
938. Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. *JAMA*, 326(14), 1390-1399. doi:10.1001/jama.2021.15072. <https://www.ncbi.nlm.nih.gov/pubmed/34477808>
939. Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. *Allergo J Int*, 1-17. doi:10.1007/s40629-021-00165-7. <https://www.ncbi.nlm.nih.gov/pubmed/33898162>
940. Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). *Allergo J Int*, 30(2), 51-55. doi:10.1007/s40629-020-00160-4. <https://www.ncbi.nlm.nih.gov/pubmed/33643776>
941. Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. *J Pediatr*. doi:10.1016/j.jpeds.2021.12.025. <https://www.ncbi.nlm.nih.gov/pubmed/34952008>
942. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to "Why are we vaccinating children against COVID-19?" [*Toxicol. Rep.* 8C (2021) 1665-1684 / 1193]. *Toxicol Rep*, 8, 1981. doi:10.1016/j.toxrep.2021.10.003. <https://www.ncbi.nlm.nih.gov/pubmed/34642628>
943. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? *Toxicol Rep*, 8, 1665-1684. doi:10.1016/j.toxrep.2021.08.010. <https://www.ncbi.nlm.nih.gov/pubmed/34540594>
944. Kreamsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . . Grupo, C.-N.-S. (2021). Seguridad e inmunogenicidad de una vacuna candidata a nanopartícula lipídica de ARNm contra el SARS-CoV-2: un ensayo clínico aleatorizado de fase 1. *Wien Klin Wochenschr*, 133(17-18), 931-941. doi:10.1007/s00508-021-01922-y. <https://www.ncbi.nlm.nih.gov/pubmed/34378087>

945. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidencia de un aumento de las tasas de avance de las variantes de SARS-CoV-2 de preocupación en individuos vacunados con BNT162b2-ARNm. *Nat Med*, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-7. <https://www.ncbi.nlm.nih.gov/pubmed/34127854>
946. Kwan, M. Y. W., Chua, G. T., Chow, C.B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). Vacuna CONTRA el ARNm COVID y miocarditis en adolescentes. *Hong Kong Med J*, 27(5), 326-327. doi:10.12809/hkmj215120. <https://www.ncbi.nlm.nih.gov/pubmed/34393110>
947. Lee, E., Chew, N. W. S., Ng, P. y Yeo, T. J. (2021). Respuesta a "Carta al editor: La miocarditis debe considerarse en aquellos con un aumento de troponina y arterias coronarias sin obstrucciones después de la vacunación PfizerBioNTech COVID-19". *QJM*. doi:10.1093/qjmed/hcab232. <https://www.ncbi.nlm.nih.gov/pubmed/34463770>
948. Lee, E. J., Cines, D.B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J.B. (2021). Trombocitopenia tras la vacunación contra el SARS-CoV-2 de Pfizer y Moderna. *Am J Hematol*, 96(5), 534-537. doi:10.1002/ajh.26132. <https://www.ncbi.nlm.nih.gov/pubmed/33606296>
949. Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Miocarditis después de la vacunación contra la COVID-19: una serie de casos. *Vacuna*, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. <https://www.ncbi.nlm.nih.gov/pubmed/34535317>
950. Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Seguridad e inmunogenicidad de la vacuna de ARNm del SARS-CoV-2 BNT162b1 en adultos chinos jóvenes y mayores: un estudio aleatorizado, controlado con placebo, doble ciego de fase 1. *Nat Med*, 27(6), 1062-1070. doi:10.1038/s41591-021-01330-9. <https://www.ncbi.nlm.nih.gov/pubmed/33888900>
951. Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X. y Lu, Z. K. (2021). Miocarditis y pericarditis después de la vacunación contra la COVID-19: desigualdades en la edad y los tipos de vacunas. *J Pers Med*, 11(11). doi:10.3390/jpm11111106. <https://www.ncbi.nlm.nih.gov/pubmed/34834458>
952. Lim, Y., Kim, M.C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Informe de caso: Miocarditis fulminante aguda y shock cardiogénico después de la enfermedad por coronavirus de ARN mensajero 2019 Vacunación que requiere reanimación cardiopulmonar extracorpórea. *Frente Cardiovasc Med*, 8, 758996. doi:10.3389/fcvm.2021.758996. <https://www.ncbi.nlm.nih.gov/pubmed/34778411>
953. Long, S. S. (2021). Información importante sobre la miopericarditis después de la vacunación pfizer contra el ARNm COVID-19 en adolescentes. *J Pediatr*, 238, 5. doi:10.1016/j.jpeds.2021.07.057. <https://www.ncbi.nlm.nih.gov/pubmed/34332972>
954. Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Miocarditis y pericarditis después de la vacunación con ARNm covid-19: consideraciones prácticas para los proveedores de atención. *Can J Cardiol*, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001. <https://www.ncbi.nlm.nih.gov/pubmed/34375696>
955. Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., . . . Eberhardt, C. S. (2021). Respuestas robustas de células T en pacientes tratados con anti-CD20 después de la vacunación contra la COVID-19: un estudio de cohorte prospectivo. *Clin Infect Dis*. doi:10.1093/cid/ciab954. <https://www.ncbi.nlm.nih.gov/pubmed/34791081>
956. Mangat, C., & Milosavljevic, N. (2021). La vacunación BNT162b2 durante el embarazo protege tanto a la madre como al bebé: anticuerpos anti-SARS-CoV-2 S persistentemente positivos en un bebé a los 6 meses de edad. *Caso Rep Pediatr*, 2021, 6901131. doi:10.1155/2021/6901131. <https://www.ncbi.nlm.nih.gov/pubmed/34676123>
957. Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S. (2021). Seguridad de la administración de la vacuna contra el ARNm BNT162b2 (Pfizer-BioNTech) contra la COVID-19 en jóvenes y adultos jóvenes con antecedentes de leucemia linfoblástica aguda y alergia a la PEG-asparaginasa. *Pediatr Blood Cancer*, 68(11), e29295. doi:10.1002/pbc.29295. <https://www.ncbi.nlm.nih.gov/pubmed/34398511>
958. Martins-Filho, P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K.B., Souza Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021). Desigualdades socioeconómicas e incidencia y mortalidad de

- COVID-19 en niños brasileños: un estudio nacional basado en registros. *Salud Pública*, 190, 4-6. doi:10.1016/j.puhe.2020.11.005. <https://www.ncbi.nlm.nih.gov/pubmed/33316478>
959. McLean, K., & Johnson, T. J. (2021). Miopericarditis en un varón adolescente previamente sano después de la vacunación contra el COVID-19: un informe de caso. *Acad Emerg Med*, 28(8), 918-921. doi:10.1111/acem.14322. <https://www.ncbi.nlm.nih.gov/pubmed/34133825>
960. Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. (2021). Miocarditis después de la vacuna BNT162b2 mRNA contra Covid-19 en Israel. *N Engl J Med*, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730. <https://www.ncbi.nlm.nih.gov/pubmed/34614328>
961. Minocha, P. K., Better, D., Singh, R. K. y Hoque, T. (2021). Recurrencia de la miocarditis aguda asociada temporalmente con la recepción de la vacuna contra la enfermedad por coronavirus mRNA 2019 (COVID-19) en un adolescente masculino. *J Pediatr*, 238, 321-323. doi:10.1016/j.jpeds.2021.06.035. <https://www.ncbi.nlm.nih.gov/pubmed/34166671>
962. Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . . Patalon, T. (2021). Correlación de las infecciones por SARS-CoV-2 con el tiempo transcurrido desde la vacuna. *Nat Commun*, 12(1), 6379. doi:10.1038/s41467-021-26672-3. <https://www.ncbi.nlm.nih.gov/pubmed/34737312>
963. Moffitt, K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021). Análisis del transcriptoma de *Staphylococcus aureus* en abscesos pediátricos de tejidos blandos y comparación con infecciones murinas. *Infectar a Immun*, 89(4). doi:10.1128/IAI.00715-20. <https://www.ncbi.nlm.nih.gov/pubmed/33526560>
964. Mohamed, L., Madsen, A.M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M. G., Benn, C. S., & Kofoed, P. E. (2021). Reactivación de las cicatrices de la vacunación BCG después de la vacunación con vacunas mRNA-Covid: dos informes de casos. *BMC Infect Dis*, 21(1), 1264. doi:10.1186/s12879-021-06949-0. <https://www.ncbi.nlm.nih.gov/pubmed/34930152>
965. Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr. (2021). Miocarditis después de la inmunización con vacunas de ARNm CONTRA EL COVID-19 en miembros del ejército de los Estados Unidos. *JAMA Cardiol*, 6(10), 1202-1206. doi:10.1001/jamacardio.2021.2833. <https://www.ncbi.nlm.nih.gov/pubmed/34185045>
966. Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). Miocarditis después de una vacuna de ARN mensajero COVID-19: una serie de casos japoneses. *Intern Med*. doi:10.2169/internalmedicine.8731-21. <https://www.ncbi.nlm.nih.gov/pubmed/34840235>
967. Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021). Miocarditis aguda asociada con la vacunación contra el COVID-19: un informe de caso. *J Casos cardiovasculares*. doi:10.1016/j.jccase.2021.11.006. <https://www.ncbi.nlm.nih.gov/pubmed/34876937>
968. Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou, M. G., . . . Sfikakis, P. P. (2021). Respuesta efectiva al daño del ADN después de un desafío inmune agudo pero no crónico: vacuna contra el SARS-CoV-2 versus lupus eritematoso sistémico. *Clin Immunol*, 229, 108765. doi:10.1016/j.clim.2021.108765. <https://www.ncbi.nlm.nih.gov/pubmed/34089859>
969. Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U.B., . . . Stensballe, L. G. (2022). Incidencia poblacional de miopericarditis después de la vacunación contra la COVID-19 en adolescentes daneses. *Pediatr Infect Dis J*, 41(1), e25-e28. doi:10.1097/INF.0000000000003389. <https://www.ncbi.nlm.nih.gov/pubmed/34889875>
970. Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., . . . Hofmann, M. (2021). Movilización rápida y estable de linfocitos T CD8(+) mediante la vacuna de ARNm contra el SARS-CoV-2. *Naturaleza*, 597(7875), 268-273. doi:10.1038/s41586-021-03841-4. <https://www.ncbi.nlm.nih.gov/pubmed/34320609>
971. Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021). Epidemiología y características clínicas de la miocarditis/ pericarditis antes de la introducción de la vacuna de ARNm CONTRA la COVID-19 en niños coreanos: un estudio multicéntrico. *J Korean Med Sci*, 36(32), e232. doi:10.3346/jkms.2021.36.e232. <https://www.ncbi.nlm.nih.gov/pubmed/34402230>
972. Park, J., Brekke, D. R., & Bratincsak, A. (2021). Miocarditis autolimitada que se presenta con dolor torácico y elevación del segmento ST en adolescentes después de la vacunación con la vacuna BNT162b2 mRNA. *Cardiol Joven*, 1-4. doi:10.1017/S1047951121002547. <https://www.ncbi.nlm.nih.gov/pubmed/34180390>



973. Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Hallazgos de resonancia magnética cardiovascular en pacientes adultos jóvenes con miocarditis aguda después de la vacunación de ARNm contra la COVID-19: una serie de casos. *J Cardiovasc Magn Reson*, 23(1), 101. doi:10.1186/s12968-021-00795-4. <https://www.ncbi.nlm.nih.gov/pubmed/34496880>
974. Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Riesgos de miocarditis, pericarditis y arritmias cardíacas asociados con la vacunación contra el COVID-19 o la infección por SARS-CoV-2. *Nat Med*. doi:10.1038/s41591-021-01630-0. <https://www.ncbi.nlm.nih.gov/pubmed/34907393>
975. Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021). Miocarditis aguda después de la vacunación de Comirnaty en un hombre sano con infección previa por SARS-CoV-2. *Radiol Case Rep*, 16(11), 3321-3325. doi:10.1016/j.radcr.2021.07.082. <https://www.ncbi.nlm.nih.gov/pubmed/34367386>
976. Pérez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodríguez-Porcel, M., Johnson, M., . . . Swift, M. D. (2021). Miocarditis después de la vacuna de ARNm covid-19: una serie de casos y determinación de la tasa de incidencia. *Clin Infect Dis*. doi:10.1093/cid/ciab926. <https://www.ncbi.nlm.nih.gov/pubmed/34734240>
977. Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . . Peruzzi, M. (2021). Una encuesta global instantánea sobre los efectos secundarios de las vacunas COVID-19 entre profesionales de la salud y fuerzas armadas con un enfoque en el dolor de cabeza. *Panminerva Med*, 63(3), 324-331. doi:10.23736/S0031-0808.21.04435-9. <https://www.ncbi.nlm.nih.gov/pubmed/34738774>
978. Pinana, J. L., López-Corral, L., Martino, R., Montoro, J., Vázquez, L., Pérez, A., . . . Terapia celular, G. (2022). Detección de anticuerpos reactivos al SARS-CoV-2 tras la vacunación contra el SARS-CoV-2 en receptores de trasplante de células madre hematopoyéticas: Encuesta prospectiva del Grupo Español de Trasplante y Terapia Celular de Células Madre Hematopoyéticas. *Am J Hematol*, 97(1), 30-42. doi:10.1002/ajh.26385. <https://www.ncbi.nlm.nih.gov/pubmed/34695229>
979. Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . . André, N. (2021). La vacuna BNT162b2 mRNA COVID-19 en adolescentes y adultos jóvenes con cáncer: Una experiencia monocéntrica. *Eur J Cáncer*, 154, 30-34. doi:10.1016/j.ejca.2021.06.002. <https://www.ncbi.nlm.nih.gov/pubmed/34233234>
980. Sánchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A. y Hanneman, K. (2021). Evaluación de la resonancia magnética cardíaca de la inflamación miocárdica no isquémica: revisión y actualización del estado del arte sobre la miocarditis asociada con la vacunación contra covid-19. *Imágenes de cardiotorrac radiol*, 3(6), e210252. doi:10.1148/ryct.210252. <https://www.ncbi.nlm.nih.gov/pubmed/34934954>
981. Schauer, J., Buddhé, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., & Portman, M. A. (2021). Miopericarditis después de la vacuna contra la enfermedad por coronavirus del ácido ribonucleico mensajero de Pfizer en adolescentes. *J Pediatr*, 238, 317-320. doi:10.1016/j.jpeds.2021.06.083. <https://www.ncbi.nlm.nih.gov/pubmed/34228985>
982. Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., . . . Schmeling, A. (2021). Investigación post mortem de muertes después de la vacunación con vacunas COVID-19. *Int J Legal Med*, 135(6), 2335-2345. doi:10.1007/s00414-021-02706-9. <https://www.ncbi.nlm.nih.gov/pubmed/34591186>
983. Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . . . Gummert, J. (2021). Mala respuesta humoral y de células T a la vacuna de ARN mensajero del SARS-CoV-2 de dos dosis BNT162b2 en receptores de trasplante cardiotorácico. *Clin Res Cardiol*, 110(8), 1142-1149. doi:10.1007/s00392-021-01880-5. <https://www.ncbi.nlm.nih.gov/pubmed/34241676>
984. Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021). Hallazgos de la autopsia y relación de causalidad entre la muerte y la vacunación contra la COVID-19: una revisión sistemática. *J Clin Med*, 10(24). doi:10.3390/jcm10245876. <https://www.ncbi.nlm.nih.gov/pubmed/34945172>

985. Sharif, N., Alzahrani, K. J., Ahmed, S. N. y Dey, S. K. (2021). Eficacia, inmunogenicidad y seguridad de las vacunas contra la COVID-19: una revisión sistemática y un metanálisis. *Immunol frontal*, 12, 714170. doi:10.3389/fimmu.2021.714170. <https://www.ncbi.nlm.nih.gov/pubmed/34707602>
986. Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Márquez, P., Liu, R., . . . Shimabukuro, T. T. (2021). Monitoreo de seguridad de la vacuna Janssen (Johnson & Johnson) COVID-19 - Estados Unidos, marzo-abril de 2021. *MMWR Morb Mortal Wkly Rep*, 70(18), 680-684. doi:10.15585/mmwr.mm7018e2. <https://www.ncbi.nlm.nih.gov/pubmed/33956784>
987. Shazley, O., & Alshazley, M. (2021). Un hombre de 52 años con COVID positivo presentó tromboembolismo venoso y coagulación intravascular diseminada después de la vacunación de Johnson & Johnson: un estudio de caso. *Cureus*, 13(7), e16383. doi:10.7759/cureus.16383. <https://www.ncbi.nlm.nih.gov/pubmed/34408937>
988. Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A. (2021). Miocarditis tras la vacunación contra la COVID-19: estudio de resonancia magnética. *Eur Heart J Cardiovasc Imaging*. doi:10.1093/ehjci/jeab230. <https://www.ncbi.nlm.nih.gov/pubmed/34739045>
989. Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021). Miocarditis aguda después de la vacunación con ARNm de COVID-19 en adultos de 18 años o más. *JAMA Intern Med*, 181(12), 1668-1670. doi:10.1001/jamainternmed.2021.5511. <https://www.ncbi.nlm.nih.gov/pubmed/34605853>
990. Singer, M. E., Taub, I.B., & Kaelber, D.C. (2021). Riesgo de miocarditis por infección por COVID-19 en personas menores de 20 años: un análisis basado en la población. medRxiv. doi:10.1101/2021.07.23.21260998. <https://www.ncbi.nlm.nih.gov/pubmed/34341797>
991. Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K. (2021). Muertes en niños y jóvenes en Inglaterra después de la infección por SARS-CoV-2 durante el primer año pandémico. *Nat Med*. doi:10.1038/s41591-021-01578-1. <https://www.ncbi.nlm.nih.gov/pubmed/34764489>
992. Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E. (2021). Lesión cardíaca transitoria en adolescentes que reciben la vacuna BNT162b2 mRNA COVID-19. *Pediatr Infect Dis J*, 40(10), e360-e363. doi:10.1097/INF.00000000000003235. <https://www.ncbi.nlm.nih.gov/pubmed/34077949>
993. Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Muñoz, F.M., & Devaraj, S. (2021). Anticuerpos anti-pico del SARS-CoV-2 después de la vacunación en el trasplante cardíaco pediátrico: un primer informe. *J Trasplante de Corazón y Pulmón*. doi:10.1016/j.healun.2021.11.001. <https://www.ncbi.nlm.nih.gov/pubmed/34911654>
994. Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T.M., Schiebler, M. L. y Reeder, S.B. (2021). Miocarditis asociada con la vacunación contra el ARNm covid-19. *Radiología*, 301(2), E409-E411. doi:10.1148/radiol.2021211430. <https://www.ncbi.nlm.nih.gov/pubmed/34282971>
995. Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Asociación temporal entre la vacuna COVID-19 Ad26.COV2.S y la miocarditis aguda: un informe de caso y una revisión de la literatura. *Cardiovasc Revasc Med*. doi:10.1016/j.carrev.2021.08.012. <https://www.ncbi.nlm.nih.gov/pubmed/34420869>
996. Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. *Eur Heart J Case Rep*, 5(8), ytab319. doi:10.1093/ehjcr/ytab319. <https://www.ncbi.nlm.nih.gov/pubmed/34514306>
997. Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021). Miocarditis eosinofílica después de la vacunación contra la enfermedad por coronavirus 2019 (COVID-19). *Circ J*. doi:10.1253/circj. CJ-21-0935. <https://www.ncbi.nlm.nih.gov/pubmed/34955479>
998. Equipo, C.C.-R., Food, & Drug, A. (2021). Reacciones alérgicas, incluida la anafilaxia después de recibir la primera dosis de la vacuna Pfizer-BioNTech COVID-19 - Estados Unidos, del 14 al 23 de diciembre de 2020. *MMWR Morb Mortal Wkly Rep*, 70(2), 46-51. doi:10.15585/mmwr.mm7002e1. <https://www.ncbi.nlm.nih.gov/pubmed/33444297>
999. Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., . . . Gaglani, M. (2021). Prevención y Atenuación del Covid-19 con las Vacunas BNT162b2 y mRNA-1273. *N Engl J Med*, 385(4), 320-329. doi:10.1056/NEJMoa2107058. <https://www.ncbi.nlm.nih.gov/pubmed/34192428>
1000. Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021). Perimiocarditis después de la vacunación contra el COVID-19. *Clin Med Insights Cardiol*, 15 años, 11795468211056634. doi:10.1177/11795468211056634. <https://www.ncbi.nlm.nih.gov/pubmed/34866957>
1001. Truong, D. T., Dionne, A., Muniz, J.C., McHugh, K. E., Portman, M. A., Lambert, L.M., . . . Newburger, J. W. (2021). Miocarditis clínicamente presunta relacionada temporalmente con la vacunación contra el

COVID-19 en adolescentes y adultos jóvenes. Circulación.

doi:10.1161/CIRCULATIONAHA.121.056583. <https://www.ncbi.nlm.nih.gov/pubmed/34865500>

1002. Tutor, A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021). Espectro de sospecha de miocardiopatía por COVID-19: una serie de casos. *Curr Probl Cardiol*, 46(10), 100926. doi:10.1016/j.cpcardiol.2021.100926. <https://www.ncbi.nlm.nih.gov/pubmed/34311983>
1003. Umei, T.C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021). Recurrencia de la miopericarditis después de la vacunación con ARNm contra la COVID-19 en un adolescente varón. *CJC Abierto*. doi:10.1016/j.cjco.2021.12.002. <https://www.ncbi.nlm.nih.gov/pubmed/34904134>
1004. Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y. (2021). Miocarditis y otras complicaciones cardiovasculares de las vacunas COVID-19 basadas en ARNm. *Cureus*, 13(6), e15576. doi:10.7759/cureus.15576. <https://www.ncbi.nlm.nih.gov/pubmed/34277198>
1005. Visclosky, T., Theyyuni, N., Klekowski, N., & Bradin, S. (2021). Miocarditis después de la vacuna de ARNm contra el COVID-19. *Pediatr Emerg Care*, 37(11), 583-584. doi:10.1097/PEC.0000000000002557. <https://www.ncbi.nlm.nih.gov/pubmed/34731877>
1006. Warren, C.M., Snow, T. T., Lee, A. S., Shah, M.M., Heider, A., Blomkalns, A., . . . Nadeau, K.C. (2021). Evaluación de reacciones alérgicas y anafilácticas a las vacunas de ARNm COVID-19 con pruebas confirmatorias en un sistema de salud regional de ee. UU. *JAMA Netw Open*, 4(9), e212524. doi:10.1001/jamanetworkopen.2021.25524. <https://www.ncbi.nlm.nih.gov/pubmed/34533570>
1007. Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Miocarditis después de la vacunación BNT162b2 en un hombre sano. *Am J Emerg Med*, 50, 815 e811-815 e812. doi:10.1016/j.ajem.2021.06.051. <https://www.ncbi.nlm.nih.gov/pubmed/34229940>
1008. Weitzman, E. R., Sherman, A.C., & Levy, O. (2021). Actitudes de la vacuna contra el ARNm del SARS-CoV-2 expresadas en el comentario público de la FDA de ee. UU.: Necesidad de una asociación público-privada en un sistema de inmunización de aprendizaje. *Frente salud pública*, 9, 695807. doi:10.3389/fpubh.2021.695807. <https://www.ncbi.nlm.nih.gov/pubmed/34336774>
1009. Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021). Trombocitopenia, incluida la trombocitopenia inmune después de recibir las vacunas de ARNm contra la COVID-19 notificadas al Sistema de Notificación de Eventos Adversos a las Vacunas (VAERS). *Vacuna*, 39(25), 3329-3332. doi:10.1016/j.vaccine.2021.04.054. <https://www.ncbi.nlm.nih.gov/pubmed/34006408>
1010. Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R. (2021). Miocarditis después de la vacunación contra el Covid-19 en una gran organización de atención médica. *N Engl J Med*, 385(23), 2132-2139. doi:10.1056/NEJMoa2110737. <https://www.ncbi.nlm.nih.gov/pubmed/34614329>
1011. Zimmermann, P., & Curtis, N. (2020). ¿Por qué el COVID-19 es menos grave en los niños? Una revisión de los mecanismos propuestos que subyacen a la diferencia relacionada con la edad en la gravedad de las infecciones por SARS-CoV-2. *Arch Dis Child*. doi:10.1136/archdischild-2020-320338. <https://www.ncbi.nlm.nih.gov/pubmed/33262177>

TAMBIÉN TE PUEDE INTERESAR

**[Informe de lesiones por vacunas Contra el Covid 19 de Vaers 12 días](#)**

24 febrero 2021

**[Derechos y recursos del Reino Unido para los denunciantes](#)**

11 marzo 2019

**[El Dr. Zalenko sacrifica la vacuna contra el Covid19 y la vacuna contra el Covid19](#)**

12 agosto 2021